Dominance of Alpha and Iota variants in SARS-CoV-2 vaccine breakthrough infections in New York City

Author Affiliations:

Ralf Duerr, MD, PhD^{1*}, Dacia Dimartino², PhD, Christian Marier², Paul Zappile², Guiqing Wang, MD, PhD³, Jennifer Lighter, MD⁴, Brian Elbel, PhD⁵, Andrea Troxel, PhD⁵ and Adriana Heguy, PhD _{2,3}*

- 1. Department of Microbiology, NYU Grossman School of Medicine
- 2. Genome Technology Center, Office of Science and Research, NYU Langone Health
- 3. Department of Pathology, NYU Grossman School of Medicine
- 4. Department of Pediatric Infectious Diseases, NYU Grossman School of Medicine
- 5. Department of Population Health, NYU Grossman School of Medicine
- * Co-corresponding authors

Conflict of Interest Statement: The authors declare that no conflict of interest exists

Abstract

The efficacy of COVID-19 mRNA vaccines is high, but breakthrough infections still occur. We compared the SARS-CoV-2 genomes of 67 breakthrough cases after full vaccination with BNT162b2 (Pfizer/BioNTech), mRNA-1273 (Moderna), or JNJ-78436735 (Janssen) to unvaccinated controls (February-April 2021) in metropolitan New York, including their phylogenetic relationship, distribution of variants, and full spike mutation profiles. Their median age was 45 years; seven required hospitalization and one died. Most breakthrough infections (54/67) occurred with B.1.1.7 (Alpha) or B.1.526 (lota). Among the 7 hospitalized cases, 5 were infected with B.1.1.7, including 1 death. Both unmatched and matched statistical analyses considering age, sex, vaccine type, and study month as covariates supported the null hypothesis of equal variant distributions between vaccinated and unvaccinated in chi-squared and McNemar tests (p>0.1) highlighting a high vaccine efficacy against B.1.1.7 and B.1.526. There was no clear association among breakthroughs between type of vaccine received and variant. In the vaccinated group, spike mutations in the N-terminal domain and receptor-binding domain that have been associated with immune evasion were overrepresented. The evolving dynamic of SARS-Co-V2 variants requires broad genomic analyses of breakthrough infections to provide real-life information on immune escape mediated by circulating variants and their spike mutations.

INTRODUCTION

The novel betacoronavirus SARS-CoV-2 arose as a new human pathogen at the end of 2019, and rapidly spread to every corner of the globe, causing a pandemic of enormous proportions, with 179 million cumulative infections and almost 4 million deaths counted worldwide as of mid-June 2021¹. As soon as the causative agent was identified and sequenced², massive efforts to develop vaccines were initiated and tested simultaneously in multiple clinical trials. These efforts led to the rapid deployment of several of these vaccines by December 2020, less than a year after the first SARS-CoV-2 viral sequence had been determined. In the United States, vaccination started in December 2020, using two novel mRNA-based vaccines, BNT162b2 (Pfizer/BioNTech), and mRNA-1273 (Moderna), both using the SARS-CoV-2 spike mRNA sequence of the original Wuhan variant. The Janssen COVID-19 vaccine, JNJ-78436735, was also deployed shortly after the mRNA vaccines, and these vaccines were shown to have high efficacy in clinical trials ³⁻⁵. With millions of people vaccinated in multiple countries, they have proven to be highly effective in the real world ⁶⁻¹², although a very small percentage of breakthrough infections have occurred, as expected ¹³⁻²¹. Contemporaneously with the vaccination efforts in several countries, new SARS-CoV-2 variants emerged, four of which were designated by the WHO as variants of concern (VOC), B.1.1.7 or Alpha, B.1.351 or Beta, P.1 or Gamma, and B.1.617.2 or Delta, which arose originally in the UK, South Africa, Brazil, and India, respectively ^{22, 23}. VOCs are classified as such if they are more transmissible, cause more severe disease or a significant reduction in neutralization by antibodies generated via previous infection or after vaccination. In addition, there are variants of interest (VOI), which carry mutations that have been associated with changes to receptor binding, reduced neutralization by anti-SARS-CoV-2 antibodies, or may increase transmissibility or severity. One of these variants is B.1.526 (lota),

which arose in New York City in late December 2020 ^{24, 25}. Although it is not yet clear that any particular VOC and VOI is associated with vaccine breakthrough, data from Israel suggest that there might be higher vaccine breakthrough rates with the B.1.351 variant ¹⁷. In addition, it is possible that certain amino acid mutations in spike, irrespective of affiliation to a specific VOC or VOI, are critical for vaccine breakthrough, but this has only been rudimentarily studied ¹⁸. There is scarcity of data about determinants of vaccine breakthrough. The few reported studies have included breakthrough cases after first or second immunization, however, breakthrough cases after full vaccination remained moderate or low ¹³⁻²¹. Thus, comprehensive studies with site-specific mutation analyses are needed on a larger number of fully vaccinated individuals from different geographic regions. Here, we added such data from the NY metropolitan area. We carried out full SARS-CoV-2 genome sequencing of SARS-CoV-2-positive individuals, 14 days after their completed vaccination series with mostly Pfizer and Moderna vaccines in the multicenter NYU Langone Health System. Analyses included statistical comparison of variant distribution as well as mutation rates at every residue in spike between vaccinated and unvaccinated individuals.

METHODS

Study design and sample collection. The design is an observational case-control study of SARS-CoV-2 vaccine breakthrough infections in the NYU Langone Health system, a large healthcare system in the New York City metro area, with primary care hospitals located in Manhattan (New York County), Brooklyn (Kings County) and Nassau County (Long Island). The case group consisted of individuals who tested positive by real-time RT-PCR for SARS-CoV-2 RNA regardless of cycle threshold (Ct), any time after 14 days of inoculation with the second dose of BNT162b2 (Pfizer/BioNTech) or mRNA-1273 (Moderna) vaccines, or with the single dose COVID Janssen vaccine, according to our electronic health records (EHR). The control group consisted of fullgenome sequenced SARS-CoV-2 positive cases in our health system who were randomly selected for SARS-CoV-2 genomic surveillance, had Ct ≤30, and were collected in the same time period as the breakthrough infections. Nasopharyngeal swabs were sampled from individuals suspected to have an infection with SARS-CoV-2 as part of clinical diagnostics or hospital admittance. Samples were collected in 3 mL viral transport medium (VTM; Copan universal transport medium or equivalent). Clinical testing was performed using various FDA emergency use authorization (EUA)-approved platforms for detection of SARS-CoV-2, i.e., the Roche Cobas 6800 SARS-CoV-2 (90% of the samples in this study) and Cepheid Xpert SARS-CoV-2 or SARS-CoV-2/Flu/RSV assays.

RNA extraction, cDNA synthesis, library preparation and sequencing

RNA was extracted from 400 µl of each nasopharyngeal swab specimens using the MagMAX[™] Viral/Pathogen Nucleic Acid Isolation Kit on the KingFisher flex system (Thermo Fisher Scientific) following the manufacturer's instructions. Total RNA (11 µl) was converted to first strand cDNA by random priming using the Superscript IV first-strand synthesis system (Invitrogen, ref#

180901050). Libraries were prepared using Swift Normalase Amplicon SARS-CoV-2 Panel (SNAP) and SARS-CoV-2 additional Genome Coverage Panel (Cat# SN-5X296 core kit, 96rxn), using 10 µl of first strand cDNA, following the manufacturer's instructions ²⁶. Final libraries were run on Agilent Tapestation 2200 with high sensitivity DNA Screentape to verify the amplicon size of about 450 bp. Normalized pools were run on the Illumina NovaSeq 6000 system with the SP 300 cycle flow cell. Run metrics were paired-end 150 cycles with dual indexing reads. Typically, two pools representing two full 96 well plates (192 samples) were sequenced on each SP300 NovaSeq flow cell.

Sequenced read processing

Sequencing reads were demultiplexed using the Illumina bcl2fastq2 Conversion Software v2.20 and adapters and low-quality bases were trimmed with Trimmomatic v0.36²⁷. BWA v0.7.17²⁸ was utilized for mapping reads to the SARS-CoV-2 reference genome (NC_045512.2, wuhCor1) and mapped reads were soft-clipped to remove SNAP tiled primer sequences using Primerclip v0.3.8²⁹. BCFtools v1.9³⁰ was used to call mutations and assemble consensus sequences, which were then assigned phylogenetic lineage designations according to PANGO nomenclature ³¹. Sequences that did not yield a near-complete viral genome (<23,000bp, <4000x coverage) were discarded from further analysis.

Phylogenetic analyses

SARS-CoV-2 full genome sequences were aligned using Mafft v.7³². The alignment was cropped to base pairs 202-29657 according to the Wuhan-Hu-1 reference to remove N- and C-terminal regions with unassigned base pairs. Maximum likelihood IQ trees were performed using the IQ-TREE XSEDE tool, multicore version 2.1.2, on the Cipres Science gateway v.3.3³³. GTR+I+G was chosen as the best-fit substitution model. Support values were generated with 1,000 bootstrap replicates and the ultrafast bootstrapping method. Phylogenetic trees were visualized in Interactive Tree Of Life (iTOL) v.6³⁴. The tree was constructed using 67 vaccine breakthrough and 1,187 unvaccinated control SARS-CoV-2 sequences from our NYU cohort (greater NYC area) together with 3,802 global reference sequences for a total of 5,056 SARS-CoV-2 genomic sequences. The reference sequences were retrieved from a Nextstrain build with North America-focused global subsampling [4] and included 1,361 other US sequences.

Mutation analysis

Spike amino acid counts and calculations of site-specific mutation frequencies compared to Wuhan-Hu-1 as reference were done on MAFFT-aligned SARS-CoV-2 sequences using R³⁵ and R Studio³⁶ using scripts based on the seqinr and tidyverse (dplyr, lubridate, magrittr) packages. The calculations exclusively considered residues that were accurately covered by sequencing, i.e., non-ambiguous characters and gaps. Fisher exact tests and multiplicity corrections (Benjamini-Hochberg) were done in Program R/RStudio. Multiplicity corrected P values (q) <0.05 were considered significant. Highlighter analyses were performed on MAFFT-aligned SARS-CoV-2 amino acid sequences of the spike genomic region. SARS-CoV-2 vaccine breakthrough sequences were compared to Wuhan-Hu-1 as master using the Highlighter tool provided by the Los Alamos HIV sequence database ³⁷.

Statistical analysis

To address confounding and other sources of bias arising from the use of observational data, we estimated a propensity score for the likelihood of full vaccination, and matched vaccinated to unvaccinated patients, including age, sex, county of residence, and study month (February, March, April 2021) as covariates ³⁸. Propensity-score matching was implemented using the nearest neighbor strategy using a 1:1 ratio without replacement, with the MatchIt algorithm in RStudio version 1.4.1106 ³⁹. Before and after matching, we evaluated the presence of three Pango lineages, B.1.1.7, B.1.526 and P.1 compared to all others lineages combined. On unmatched data, we calculated a Pearson chi-squared test statistic; on matched data we calculated McNemar's test. The tables used for these calculations are in Supplementary Material (**Supplementary Tables 1 and 2**). Comparisons of Ct values and mutation counts between groups were made using non-parametric Mann-Whitney tests or Kruskal-Wallis tests with Dunn's multiplicity correction.

Study Approval. This study was approved by the NYU Langone Health Institutional Review Board, protocol number i21-00493.

RESULTS

Alpha and lota variants dominate vaccine breakthrough infections in metropolitan New York A total of 126,367 fully vaccinated individuals were recorded in our electronic health records by April 30th, 2021, of whom the majority (123,511, 98%) were vaccinated with mRNA vaccines (Pfizer/BioNTech = 103,166 and Moderna = 20,345), and the rest (2,856) with the adenovirusbased Janssen COVID-19 vaccine, administered as single dose. We recorded 86 cases of vaccine breakthrough infection (69x Pfizer/BioNTech, 16x Moderna, and 1x Janssen) between February 1st and April 30th of 2021, representing 1.2% of the total SARS-CoV-2 positive cases in our healthcare system and 0.07% of the fully vaccinated population in our medical records. Out of the 86 cases, 67 cases (80%) yielded full SARS-CoV2 genomes (54x Pfizer/BioNTech, 12x Moderna, and 1x Janssen) that passed quality control (QC) and allowed us to determine the Pango lineage and mutations across the viral genome, including the spike gene. As expected, the 19 excluded breakthrough cases with low genome coverage and failed QC had significantly higher Ct values (median: 35, range: 31-42) than the 67 samples with full viral genome coverage (P<0.0001, Mann Whitney test), which had Ct values below 34 (median: 24, range: 13-34) (**Figure 1A**).

Although B.1.1.7 (Alpha) infection has been associated with overall higher viral load/lower Ct values ^{40, 41}, the Ct values in our recorded breakthrough infections were not significantly different for B.1.1.7 compared to B.1.526 (lota) or all other variants (**Figure 1B**). Among the 67 COVID-19 cases post-vaccination with adequate SARS-CoV-2 genome coverage, the median age was 45 years, 33 were male and 24 were female. Seven required hospitalization for COVID-19, among whom there was one death in an elderly patient with multiple comorbidities who already was on in-home oxygen previous to post-vaccination COVID-19 infection and had a lengthy stay at the ICU (**Table 1, Supplementary Table 3**).

The distribution of PANGO lineages in the 67 vaccine breakthroughs was as follows: 26 (38.8%) had B.1.1.7, 28 (41.8%) had B.1.526 (including sublineages B.1.526.1 and B.1.526.2), 1 (0.2%) had P.1, and 12 (17.9%) had other variants (**Supplementary Figure 1**). Among the 1,187 sequences from the group of unvaccinated patients, 345 (29.1%) had B.1.1.7, 487 (41.0%) had B.1.526 (including sublineages B.1.526.1, B.1.526.2, and B.1.526.3), 12 (1.0%) had P.1, and 343 (28.9%) had other variants. Of the seven hospitalizations, five were infected with B.1.1.7, including the fatal case, and two with B.1.526.

VOCs and VOIs are equally distributed in vaccinated and unvaccinated infections.

To compare vaccinated breakthrough infections with unvaccinated controls statistically, we included 1,187 unvaccinated individuals from the same study cohort who became SARS-CoV-2-infected in the same study months (February-April 2021) as the vaccine breakthrough cases. A chi-squared test for rejecting the null hypothesis of equal Pango lineage distributions (B.1.1.7, B.1.526, and other variants combined) between vaccinated and unvaccinated patients resulted in a p-value of 0.18.

To address confounding and other sources of bias arising from the use of observational data, we estimated a propensity score for the likelihood of full vaccination ³⁸, and successfully matched all 67 vaccinated to unvaccinated patients, including age, sex, county of residence, and study month (February, March, and April 2021) as covariates. The standardized mean difference between the matched pairs was 0.0125, reduced by 99.7 percent from 0.590 prior to matching.

Supplementary Table 1 shows the distribution of variants in the matched pairs. McNemar's test of the null hypothesis of equal distributions between vaccinated and unvaccinated patients, assessing the three VOC/VOI separately, could not be calculated due to sparse data. When we collapsed the table to reflect all VOCs/VOIs compared to other variants, McNemar's test resulted in a p-value of 0.82 (**Supplementary Table 2**). Thus, vaccinated and unvaccinated individuals in the metropolitan New York area are similarly affected by the regionally circulating VOCs and VOIs. In addition, there is no clear association among vaccinated patients between type of vaccine received and Pango lineage (chi-squared test, p=0.36).

Widespread phylogenetic dispersal of vaccine breakthrough sequences among unvaccinated controls

As a way to ascertain potential bias in our sampling, we carried out a phylogenetic analysis of our 67 breakthrough sequences in the context of 1,187 unvaccinated SARS-CoV-2-positive controls (selected randomly as part of our greater New York catchment area genomic surveillance) together with sub-sampled sequences from the United States as well as globally, the latter two groups based on Nextstrain builds of GISAID sequences (**Figure 2**). The main variants circulating in the New York area between the months of February and April 2021 were B.1.1.7 and B.1.526 (purple). Accordingly, our vaccine breakthrough samples (orange branch symbols and gray rays) mostly engaged B.1.1.7 and B.1.526 clades and were interspersed among the unvaccinated controls as well as other United States sequences. There was no evidence of extensive clustering that might indicate onward transmissions or transmission chains of vaccine breakthrough infections. Instead, they were widely distributed and appeared to mostly involve independent clusters of infections.

Enrichment of NTD deletions and RBD escape mutations in vaccine breakthrough compared to unvaccinated control sequences.

To screen whether vaccine breakthrough preferentially occurred with distinct vaccine escape mutations, we performed a comparative analysis of spike mutations between case and control groups. In our aligned data set of 67 vaccine breakthrough and 1,187 unvaccinated control sequences, spike mutations (compared to Wuhan-Hu-1) occurred at 233 amino acid residues. While most of these sites were more frequently mutated in control cases (191 sites), and one site (D614) being equally mutated in both groups (100% D614G), 41 sites exhibited increased mutation rates in the vaccine breakthrough group (Figure 3A). Interestingly, the degree of enrichment (Δ mut) was higher at the 41 breakthrough-enriched sites compared to the 191 sites enriched in controls. Contributing factors presumably included random mutations in the absence of immune pressure in controls, adaptive selection of immune escape mutations in vaccine breakthroughs, but also uneven case numbers in both groups. When we disregarded unique mutations per data set in our calculations, the mutation analysis yielded 21 distinct spike sites with enriched mutations in breakthrough infections (Figure 3A, Supplementary Table 4). Although individual sites did not achieve significance in Fisher's exact tests, the array of sieved mutation sites drew a striking pattern of N-terminal domain (NTD) deletions (ΔV69-H70 and ΔY144), receptor-binding domain (RBD) mutations (K417, S477, E484, and N501), a mutation near the furin binding site (P681X), and also C-terminal mutations (T1027X and D1118X), all of which have been associated with enhanced immune evasion or ACE2 receptor binding, and/or recurring mutations in emerging VOCs/VOIs^{22,42}.

DISCUSSION

Our data from a large metropolitan healthcare system in the greater New York City area underline a high vaccine efficacy in fully vaccinated individuals, 14 days or longer post-last dose of vaccination. Efficacy is maintained against several circulating variants including VOCs and VOIs. Compared to the large number of SARS-CoV-2 infections among unvaccinated individuals, the recorded breakthrough cases between February and April 2021 (n=67) remained at~1% of total infections, with the caveat that both breakthrough cases as well as unvaccinated controls were not exhaustively screened and covered.

Despite the overall effectiveness of vaccination, our full spike mutation analysis revealed a broad set of spike mutations (n=21) to be elevated in the vaccine breakthrough group. It indicates that adaptive selection is in progress that may subsequently come into full effect. At this point, the breakthrough cases and differences in mutation rates between case and control groups are still too low to draw meaningful conclusions. However, the overrepresentation of functionally important spike mutations including NTD deletions Δ H69-V70 and Δ Y144 together with RBD mutations K417X, S477X, E484X, and N501X as well as P681X (near the S1/S2 interface) in the absence of a clear elevation of VOCs or VOIs may indicate a starting sieve effect at individual or combinations of functional mutations. Spike mutations and deletions

reported to confer neutralization escape *in vitro*^{23, 43, 44} might thus be responsible for a sieve effect in a real-life situation, i.e., among vaccinated individuals.

During the time of our sample and data collection, there were two major variants arising in the New York City metro area constituting about two thirds of all cases, B.1.1.7, which was first reported in the UK ⁴⁵, and B.1.526, which arose in New York City around December of 2020 ^{24, 25}. B.1.1.7 was deemed a variant of concern by the WHO and CDC and was associated with higher viral loads in infected individuals ^{40, 41}, enhanced epidemiological spread ⁴⁵⁻⁴⁷, an extended window of acute infection ⁴⁸, less effective innate and adaptive immune clearance ⁴⁹, and increased death rates in elderly patients and/or individuals with comorbidities ⁵⁰⁻⁵³. The B.1.1.7 variant, e.g., through the RBD N501Y mutation but also through NTD deletions, acquired an enhanced affinity to ACE2, higher infectivity and virulence ⁵⁴⁻⁵⁷, while maintaining sensitivity to neutralization though with slightly impaired nAb titers ^{54, 58-60}. The B.1.526 variant and its derivatives were designated VOI because of the presence of RBD mutations such as E484K or S477N that favor immune evasion ^{23, 25}.

To study whether the more transmissible B.1.1.7 or B.1.526 because of its critical RBD mutations and prevalence/place of origin in our city were overrepresented in the breakthrough cases, we performed a comparative statistical analysis. Extending a few other studies reported so far ¹³⁻²¹, we focused on a strict threshold of 14 days post last dose of vaccination, and we performed both unmatched and matched analyses side-by-side. We adjusted the confounding factors sex, age, study month, and residence area, though we are aware that other confounding factors such as biased sampling or behavioral differences between groups might also play a role.

Our finding that B.1.1.7 and B.1.526 are not preferentially represented in the vaccine breakthrough group but distributed at similar proportions as other variants in case and control groups suggests that the studied mRNA vaccines are comparably effective against these predominant variants in the NYC area. This is in agreement with recent data from Israel evaluating B.1.1.7 in this context ¹⁷. A sieve effect of the B.1.526 variant has not been studied in this detail, except for two studies with small sample sizes of n=2 and n=11 that did not allow strong conclusions ^{14, 19}. A recent CDC study reported a total number of 10,262 SARS-CoV-2 vaccine breakthrough infections across the USA as of end-April 2021 causing hospitalization in 10% of cases (n=995) ²⁰, a rate identical to our study.

Interestingly, the majority of our breakthrough infections had low Ct values (Ct <35), implying a moderate to high viral load in these cases, at least in the nasopharynx from where our samples were collected. These high viral loads suggest the possibility of transmission to others ⁶¹. Although our phylogenetic analysis does not provide evidence of transmission to others from our breakthrough cases at this time, this should be expected with the growing number of breakthrough cases in the next months. This may have significant epidemiologic and clinical significance if transmissible breakthrough infections carry specific spike mutations associated with immune evasion.

In conclusion, our data indicate that vaccine breakthrough in fully mRNA-vaccinated individuals is not more frequent with the VOC Alpha or the NY local VOI lota, which underlines the high efficacy of mRNA COVID-19 vaccines against different variants. The Alpha variant appears overrepresented in the hospitalized group, though the low case numbers of hospitalizations do not allow firm conclusions. The increased presence of mutations in key regions of the spike protein in the vaccine breakthrough group is of potential concern and requires continued monitoring. Genomic surveillance of vaccine breakthrough cases should be carried out on a broader scale throughout the United States and the entire word to achieve higher case numbers and the inclusion of different VOCs and VOIs.

Author contributions:

Ralf Duerr, MD, PhD designed the study, analyzed data and wrote the manuscript; Dacia Dimartino, PhD generated sequencing data; Christian Marier analyzed genomic data; Paul Zappile generated sequencing data; Guiqing Wang, MD, PhD collected samples and performed clinical SARS-CoV-2 detection; Jennifer Lighter, MD reviewed clinical information; Brian Elbel, PhD monitored epidemiological data and generated lists of breakthrough infections; Andrea Troxel, PhD performed statistical analyses; Adriana Heguy, PhD designed the study, generated genomic data and wrote the manuscript. All authors reviewed and edited the manuscript.

Acknowledgements. The authors wish to thank Vincent Setang and NYU Langone Health DataCore for support extracting the data for this study from clinical databases, Dr. Maria Agüero-Rosenfeld and the clinical laboratory technicians for assistance in testing, saving and retrieving specimens, especially Joanna Fung for her assistance with RNA extraction project. We also thank Dr. Joan Cangiarella for her continuous support of genomic surveillance for SARS-CoV-2 at NYULH, including providing institutional funding for this study. We are grateful to the authors and submitting laboratories who deposited data in GISAID, in particular to those whose sequences we used to create the phylogenetic tree. These are all named in Supplemental Table 5. The NYULH Genome Technology Center is partially supported by the Cancer Center Support Grant P30CA016087 at the Laura and Isaac Perlmutter Cancer Center.

Tables.

Table 1. Vaccine breakthrough study population

Sample ID (arbitrary #)	Days after completion of vaccination series	Vaccine	Hospitalization	Sex	Age range	Ct	Pango Lineage
P21-2388	31	Pfizer	No	М	31-40	18	A.2.5.2
P21-0524	28	Pfizer	No	М	21-30	33	B.1.526.2
P21-1296	40	Pfizer	No	F	41-50	31	B.1.526
P21-2376	27	Pfizer	No	F	21-30	19	B.1.526.1
P21-1416	45	Pfizer	No	F	41-50	27	B.1.2
P21-0852	54	Pfizer	No	F	21-30	22	B.1.1.7
P21-1038	22	Moderna	No	F	71-80	27	B.1.2
P21-2765	28	Moderna	Yes (COVID)	М	81-90	17	B.1.526
P21-1413	67	Pfizer	No	М	31-40	23	B.1.526
P22-1140	23	Pfizer	Yes (COVID)	М	61-70	15	B.1.526.2
P21-1407	49	Pfizer	No	Μ	31-40	28	B.1.1.519
P21-2366	57	Pfizer	Yes (not COVID)	Μ	71-80	24	B.1.526.2
P21-2383	17	Pfizer	No	М	41-50	33	B.1.526
P21-1292	33	Pfizer	Yes (COVID)	F	71-80	20	B.1.1.7
P21-1293	58	Pfizer	No	F	31-40	27	B.1.526.2
P21-1234	21	Pfizer	No	М	71-80	25	B.1.526
P21-1406	65	Pfizer	No	F	31-40	13	B.1.526.1
P21-2368	52	Pfizer	No	F	21-30	29	B.1.1.7
P21-1412	62	Pfizer	No	F	51-60	22	B.1.526.1
P21-1411	54	Pfizer	No	F	51-60	30	B.1.111
P21-1405	58	Pfizer	No	F	31-40	25	B.1.526
P21-2373	78	Pfizer	No	М	31-40	33	B.1.1.7
P21-1394	70	Pfizer	No	F	21-30	32	B.1.1.7
P21-1396	70	Pfizer	No	F	31-40	27	B.1.1.7
P21-2365	57	Pfizer	No	F	21-30	27	B.1.526.1
P21-2379	65	Pfizer	No	F	41-50	22	B.1.1.7
P21-1403	72	Pfizer	No	F	21-30	27	B.1.526
P21-1404	73	Pfizer	No	F	41-50	17	B.1.1.7
P21-2380	70	Pfizer	No	М	31-40	33	B.1.526.1
P21-1362	61	Pfizer	No	F	41-50	20	B.1.526.1
P21-1595	53	Pfizer	No	F	71-80	18	B.1.1.7

P21-1415	42	Moderna	No	Μ	61-70	24	B.1.1.7
P21-1556	85	Pfizer	No	Μ	41-50	19	B.1.526.2
P21-1993	50	Moderna	Yes (COVID)	М	81-90	23	B.1.1.7
P21-2384	50	Moderna	No	F	71-80	24	B.1.1.7
P21-1596	57	Moderna	No	М	71-80	34	B.1.1
P21-2191	68	Pfizer	No	М	31-40	18	B.1.526
P21-2192	23	Janssen	Yes (COVID)	Μ	41-50	25	B.1.1.7
P21-2738	49	Moderna	Yes (not COVID)	Μ	71-80	28	B.1.1.7
P21-1574	22	Pfizer	No	F	21-30	23	B.1
P21-1985	76	Pfizer	No	М	21-30	23	B.1.1.7
P21-2370	48	Pfizer	No	Μ	71-80	31	B.1.526
P21-1984	75	Pfizer	No	Μ	51-60	27	B.1.526.2
P21-1970	71	Moderna	No	F	31-40	22	B.1.1.7
P21-1976	89	Pfizer	No	Μ	31-40	19	B.1.526.1
P21-1992	76	Pfizer	No	Μ	41-50	21	B.1.1.7
P21-1964	78	Pfizer	No	Μ	51-60	33	B.1.1.7
P21-2385	72	Pfizer	No	Μ	51-60	29	B.1.1.7
P21-2096	88	Pfizer	No	F	31-40	33	B.1.575
P21-2080	60	Moderna	Yes (not COVID)	Μ	71-80	24	B.1.1.7
P21-2193	94	Pfizer	No	F	41-50	25	P.1
P21-2364	59	Pfizer	No	М	51-60	31	B.1.1.7
P21-2378	20	Pfizer	No	Μ	61-70	25	B.1.1
P21-2382	26	Pfizer	No	Μ	61-70	18	B.1.1.7
P21-2105	97	Pfizer	No	Μ	21-30	20	B.1.1.7
P21-2372	66	Pfizer	No	Μ	21-30	21	B.1.526
P21-2137	67	Moderna	No	F	31-40	18	B.1.526
P21-2143	55	Pfizer	Yes (not COVID)	F	81-90	20	B.1.526
P21-2371	54	Moderna	No	F	61-70	20	B.1.429
P21-2764	27	Pfizer	Yes (COVID)	F	51-60	31	B.1.1.7
P21-2124	61	Pfizer	No	F	21-30	24	B.1.526
P21-2375	105	Pfizer	No	Μ	51-60	30	B.1.526
P21-2381	64	Moderna	Yes (not COVID)	Μ	71-80	22	B.1.575
P21-2386	31	Pfizer	Yes (COVID)	F	51-60	22	B.1.1.7

P21-2594	102	Pfizer	No	F	31-40	18	B.1
P21-2573	100	Pfizer	No	F	31-40	19	B.1.1.7
P21-2592	99	Pfizer	No	F	21-30	25	B.1.526

Ct=cycle threshold from real-time RT-PCR SARS-CoV-2 test

Figures.



Figure 1. RT-qPCR Ct values in post-vaccine breakthrough infections. **A)** Ct plots of samples that yielded a full genome with sufficient coverage to determine lineage and mutations (QC passed = >23,000 bp and >4000X coverage; QC failed = <23,000 bp and <4000X coverage). **B)** Ct plots of all samples that passed QC, by lineages, B.1.1.7 (Alpha) and B.1.526 (Iota), compared to all others. Hospitalized cases are shown in larger sized black symbols. QC: quality control.



Figure 2. Maximum likelihood tree of SARS-CoV-2 vaccine breakthrough, unvaccinated matched control, and global reference sequences.

IQ tree of 5,056 SARS-CoV-2 full genome sequences (base pairs 202-29,657 according to Wuhan-Hu-1 as reference), including 67 vaccine breakthrough (orange) and 1,187 unvaccinated control SARS-CoV-2 sequences from our NYU cohort (greater NYC area) (purple) together with 1,361 other US (cyan) and 2,441 non-US global reference sequences (black). The tree was generated with a GTR+I+G substitution model and 1,000 bootstrap replicates, and the substitution scale of the tree is indicated at the bottom right. The branches of the tree are colored as indicated. Vaccine breakthrough sequences are additionally highlighted by orange triangles as branch symbols and gray rays radiating from the root to the outer rim of the tree. Hospitalizations due to COVID-19 among the vaccine breakthrough infections are indicated by black triangles (h). The variants responsible for most vaccine breakthrough infections in our study cohort are labeled with respective Pango lineages (WHO classification in parenthesis).



Figure 3. Site-specific spike mutation analysis in SARS-CoV-2 vaccine breakthrough sequences compared to unvaccinated matched controls.

A) Comparison of site-specific amino acid mutation (mut) frequencies in spike in 67 vaccine breakthrough sequences (Vacc) compared to 1,187 unvaccinated matched controls (Unvacc) from the same cohort. The Wuhan-Hu-1 sequence served as reference to call mutations per site, and all spike mutation sites of the study sequences are shown along the x-axis according to their spike position (n=233). The mirror plot displays differences of mutation frequencies between Vacc and Unvacc groups; orange bars (top) refer to higher mutation rates in Vacc sequences, whereas black bars (bottom) refer to higher mutation rates in Unvacc matched controls. **B**) Enrichment of spike mutations in SARS-CoV-2 vaccine breakthrough sequences. All sites with greater spike mutation rates in Vacc compared to Unvacc controls are shown; unique occurrences of mutations were disregarded. Mutation sites in the spike N-terminal domain (NTD), receptor binding domain (RBD), and S1/S2 interface region that have been associated with variants of concern and/or neutralization immune escape are highlighted.

Supplementary Tables.

Supplementary Table 1: SARS-CoV-2 breakthrough and unvaccinated control infections in matched pairs in New York.

				Vaccina	ated							
		B.1.1.7	3.1.1.7 B.1.526 P.1 other To									
	B.1.1.7	11	11 7 0 7									
	B.1.526	12	14	1	4	31						
Unvaccinated	P.1	0	1	0	0	1						
	other	3	6	0	1	10						
	Total	26	28	1	12	67						

Supplementary Table 2: SARS-CoV-2 breakthrough and unvaccinated control infections in matched pairs in New York

		Vaccinated										
		VOC/VOI	other	Total								
Unvaccinated	VOC/VOI	46	11	57								
	other	9	1	10								
	Total	55	12	67								

Samala	Dates after									Pango	
ID	of					Ct for				Lineage	
(arbitrary	vaccination	Vessine	Useritelization	Carr	Age	TARGET	GISAID	GISAID	GISAID	(Updated	AA Cubatinutions
#)	series	vaccine	Hospitalization	Sex	31-40	1 (0111)	Accession	virus Name	Clade	00/11)	Spike D215A, Spike D614G, Spike G142del, Spike ins215AGY, Spike L141del, Spike L452R, Spike
			not								V143del, N M234I, N P365S, N P383L, N S197L, NS3 S74F, NS7a A105S, NS8 L84S, NSP1 L4F, NSP3
P21-2388	31	Pfizer	hospitalized	М	21.20	18.45	EPI_ISL_1922872	NYULH1636	S	A.2.5.2	K839E, NSP4 F308Y, NSP4 T492I, NSP6 H11Q, NSP12 M629T
			not		21-50						T111, NSP2 T851, NSP4 L438P, NSP6 F108del, NSP6 G107del, NSP6 S106del, NSP12 P323L, NSP13
P21-0524	28	Pfizer	hospitalized	М		33.3	EPI_ISL_1423379	NYULH1002	GH	B.1.526.2	Q88H
			net		41-50						Spike A701V, Spike D253G, Spike D614G, Spike E484K, Spike L5F, Spike T95I, N H300Y, N I94V, N
P21-1296	40	Pfizer	hospitalized	F		31.42	EPI ISL 1423503	NYULH997	GH	B.1.526	G107del, NSP6 S106del, NSP12 P323L, NSP13 Q88H
-					21-30						Spike D80G, Spike D614G, Spike F157S, Spike L452R, Spike T859N, Spike Y144del, N M234I, N T205I,
021 2276	27	Dfizor	not	E		10.29	EDI ISI 1022962		CH.	P 1 526 1	NS3 P42L, NS3 P104L, NS3 Q57H, NS7a L116F, NS8 A51S, NS8 T11I, NSP2 T85I, NSP3 A861S, NSP4
F21-2370	21	FIIZEI	nospitalized	r	41-50	15.20	LFI_13L_1922802	NIOLIII025	GIT	B.1.320.1	Spike D614G, N P13L, N P67S, N P199L, NS3 G107dei, NS7 0 S100dei, NS7 0 V276i, NS7 12 F325E
			not								NSP3 P968L, NSP5 L89F, NSP6 T181I, NSP12 P323L, NSP12 V354L, NSP13 Q275L, NSP14 N129D,
P21-1416	45	Pfizer	hospitalized	F	21.20	27.32	EPI_ISL_1532785	NYULH1089	GH	B.1.2	NSP16 R216C
					21-50						Spike N3017, Spike Postn, Spike S982A, Spike T716I, Spike V70del, Spike Y144del, M G89S, N A398V, N D3L, N G204R, N R203K, N S235F,
			not								NS3 L15F, NS8 Q27stop, NS8 R52I, NS8 Y73C, NSP3 A890D, NSP3 I1412T, NSP3 T183I, NSP4 F17L,
P21-0852	54	Pfizer	hospitalized	F	71.90	22.18	EPI_ISL_1262524	NYULH656	GRY	B.1.1.7	NSP6 F108del, NSP6 G107del, NSP6 S106del, NSP12 P323L, NSP13 K460R, NSP14 S171G
			not		/1-80						NSP3 M829I, NSP4 M458I, NSP5 L89F, NSP8 A14V, NSP1 K59R, NSP1 P323L, NSP1 N129D, NSP1
P21-1038	22	Moderna	hospitalized	F		27.27	EPI_ISL_1300181	NYULH748	GH	B.1.2	R216C
			Lipspitalizad		81-90						Spike A701V, Spike D253G, Spike D614G, Spike L5F, Spike T95I, N M234I, N P199L, NS3 P42L, NS3
P21-2765	28	Moderna	for COVID	м		17.2	EPI ISL 2400382	NYULH1816	GH	B.1.526	S106del, NSP12 P323L, NSP13 Q88H
					31-40						Spike A701V, Spike D253G, Spike D614G, Spike E484K, Spike L5F, Spike T95I, N M234I, N P199L, NS3
D21 1412	67	Dfines	not			22.56		NIVLU 111 097	CU	D 1 5 2 6	P42L, NS3 P104L, NS3 Q57H, NS8 T11I, NSP2 T85I, NSP4 L438P, NSP6 F108del, NSP6 G107del, NSP6
P21-1415	67	Plizer	nospitalized	IVI	61-70	22.50	EPI_ISL_1552765	NTULH1087	ы	B.1.520	Studdel, NSP12 PS23E, NSP13 Q86H, NSP14 ALS, NSP16 P236E Spike D253G, Spike D614G, Spike O957R, Spike S477N, Spike T95E, N A414V, N P13E, N S202R, NS3
			Hospitalized								P42L, NS3 Q57H, NS7a L116F, NS8 T11I, NSP2 T85I, NSP3 G1128S, NSP3 T1022I, NSP4 L438P, NSP6
P22-1140	23	Pfizer	for COVID	М	21.40	14.70	EPI_ISL_1322825	NYULH877	GH	B.1.526.2	F108del, NSP6 G107del, NSP6 S106del, NSP12 P323L, NSP13 Q88H, NSP13 V521
			not		51-40						Spike D614G, Spike P681H, Spike T478K, Spike T732A, N G204R, N R203K, NSP1 G112C, NSP3 P141S,
P21-1407	49	Pfizer	hospitalized	М		27.6	EPI_ISL_1532784	NYULH1084	GR	B.1.1.519	NSP3 V1704F, NSP4 T492I, NSP6 I49V, NSP6 L37F, NSP9 T35I, NSP12 P323L, NSP15 L162F
			hospitalized		/1-80						Spike D253G, Spike D614G, Spike Q957R, Spike S477N, Spike 1951, N P13L, N S202R, NS3 P42L, NS3 Q57H, NS7a L116F, NS8 T11I, NSP2 T85I, NSP3 A1324T, NSP3 G1128S, NSP3 T169I, NSP4 L438P.
			but not for								NSP6 F108del, NSP6 G107del, NSP6 S106del, NSP9 D78N, NSP12 P227S, NSP12 P323L, NSP13 Q88H,
P21-2366	57	Pfizer	covid	М	44.50	24.23	EPI_ISL_1922855	NYULH1618	GH	B.1.526.2	NSP15 H337Y
			not		41-50						Spike A7017, Spike D253G, Spike D614G, Spike L484K, Spike 1951, N M234I, N P199L, NS3 P42L, NS3 Q57H, NS8 T11I, NSP2 T85I, NSP4 L438P, NSP6 F108del, NSP6 G107del, NSP6 S106del, NSP12
P21-2383	17	Pfizer	hospitalized	М		32.69	EPI_ISL_1922868	NYULH1632	GH	B.1.526	M601I, NSP12 P323L, NSP13 Q88H
					71-80						Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike N501Y, Spike P681H, Spike S982A,
											Q27stop, NS8 R52I, NS8 Y73C, NSP3 A890D, NSP3 I1412T, NSP3 M1441I, NSP3 T183I, NSP5 D34G,
			Hospitalized	-							NSP6 F108del, NSP6 G107del, NSP6 S106del, NSP12 M519L, NSP12 P227L, NSP12 P323L, NSP13
P21-1292	33	Pfizer	for COVID	F	21.40	20.38	EPI_ISL_1423499	NYULH993	GRY	B.1.1.7	A509V
			not		31-40						P42L, NS3 Q57H, NS7a L116F, NS7a R78C, NS8 T11I, NSP2 T85I, NSP3 G1128S, NSP4 L438P, NSP6
P21-1293	58	Pfizer	hospitalized	F		27.40	EPI_ISL_1423500	NYULH994	GH	B.1.526.2	F108del, NSP6 G107del, NSP6 S106del, NSP12 P323L, NSP13 Q88H
			not		71-80						Spike A701V, Spike D253G, Spike D614G, Spike E484K, Spike L5F, Spike T95I, N M234I, N P199L, NS3 P42L NS3 O57H NS8 T11L NSD1 H110V, NSD2 T85L NSD4 L438D, NSD6 E108deL NSD6 G107deL
P21-1234	21	Pfizer	hospitalized	М		25.39	EPI_ISL_1423443	NYULH937	GH	B.1.526	NSP6 S106del, NSP12 P323L, NSP13 Q88H
					31-40						Spike D80G, Spike D614G, Spike D950H, Spike F157S, Spike L452R, Spike T859N, Spike Y144del, N
P21-1406	65	Pfizer	not hospitalized	F		13.2	EPI ISI 1532774	NYULH1083	GH	B.1.526.1	M234I, N T205I, NS3 P42L, NS3 P104L, NS3 Q57H, NS8 A51S, NS8 T11I, NSP2 T85I, NSP4 A446V, NSP4 K399E, NSP4 I 438P, NSP6 F108del, NSP6 G107del, NSP6 S106del, NSP6 V278I, NSP12 P323I
				1	21-30						Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike K1191N, Spike P681H, Spike S982A,
										1	Spike T716I, Spike V70del, Spike Y144del, N D3L, N G204R, N R203K, N S235F, NS3 P240S, NS8
P21-2368	52	Pfizer	not hospitalized	F		29.21	EPI ISI 1922856	NYULH1619	GR	B.1.1.7	Q27stop, NS8 R52I, NS8 Y73C, NSP3 A890D, NSP6 F108del, NSP6 G107del, NSP6 S106del, NSP8 Q24R, NSP12 P323L, NSP13 K460R, NSP16 K160R, NSP16 T140L
. 21 2000					51-60	23.21			0	5.1.1.7	Spike D80G, Spike D614G, Spike D950H, Spike F157S, Spike L452R, Spike T859N, Spike Y144del, N
										1	E323K, N M234I, N T205I, NS3 P42L, NS3 P104L, NS3 Q57H, NS8 A51S, NS8 T11I, NSP2 T85I, NSP3
P21-1412	62	Pfizer	not hospitalized	F		22.01	EPI ISL 2202740	NYULH1086	GH	B.1.526.1	A8015, N5P4 A440V, N5P4 K399E, N5P4 L438P, N5P6 F108del, N5P6 G10/del, NSP6 S106del, NSP6 V278I, NSP12 P323L, NSP13 A469T

Supplementary Table 3: Full specifications of breakthrough infections

		1		1	51-60			1	1	1	
P21-1411	54	Pfizer	not hospitalized	F		29.62	EPI ISI 1532768	NYUL H1085	GH	B.1.111	Spike D614G, Spike N679K, N K387R, N T205I, NS3 G44E, NS3 Q57H, NS3 T223I, NS8 L57S, NSP1 114T, NSP12 P323I
D24 4405	50	Dfine	not		31-40	25.44		NY/11/1002	<u> </u>	D.4.536	Spike A701V, Spike D253G, Spike D614G, Spike E484K, Spike L5F, Spike T95I, N M234I, N P199L, NS3 P42L, NS3 057H, NS8 T11I, NSP2 T85I, NSP4 L438P, NSP6 F108del, NSP6 G107del, NSP6 S106del,
P21-1405	56	Plizer	nospitalized	r	31-40	25.11	EPI_13L_1332782	NTULH1082	ы	B.1.520	NSF12 F325E, N3F13 Q86R, NSF14 1426A Spike A222S, Spike H69del, Spike V70del, Spike Y144del, M G89S, N D3L, N D401Y, NS3 L15F, NS8
P21-2373	78	Pfizer	hospitalized	м		33.06	EPI_ISL_1922860	NYULH1623	G	B.1.1.7	S24L, NSP5 A890D, NSP4 F17L, NSP6 F1080El, NSP6 G1070El, NSP6 S1060El, NSP15 K460K, NSP14 S171G, NSP16 A83T
			not		21-30						Spike A570D, Spike D614G, Spike H69del, Spike P681H, Spike S982A, Spike T716I, Spike V70del, Spike Y144del, N D3L, N G204R, N R203K, N S235F, NS8 K68stop, NS8 Q27stop, NS8 R52I, NS8 Y73C,
P21-1394	70	Pfizer	hospitalized	F	21.40	31.96	EPI_ISL_1654609	NYULH1256	GR	B.1.1.7	NSP6 R138del, NSP6 V139del, NSP6 W140del, NSP13 A509V, NSP13 P234L
P21-1396	70	Pfizer	not hospitalized	F	51-40	27.01	EPI_ISL_1654610	NYULH1258	GR	B.1.1.7	Spike Y300, Spike 190-49, Spike 1916, Spike 1902, Spike 1903, Spike 1903, Spike 1903, Spike 1903, Spike 1904, Spik
P21-2365	57	Pfizer	not hospitalized	F	21-30	26.66	EPI_ISL_1922854	NYULH1617	GH	B.1.526.1	Spike U800, Spike U540, Spike U540, Spike 157, Spike 1432K, Spike 1432K, Spike 1859N, Spike 11440el, N M234I, N T205I, NS3 P42L, NS3 P104L, NS3 Q57H, NS8 A51S, NS8 T11I, NSP2 T85I, NSP4 A446V, NSP4 K399E, NSP4 L438P, NSP5 F223I, NSP5 R222Q, NSP6 F108del, NSP6 G107del, NSP6 S106del, NSP6 V278I, NSP7 Q63R, NSP12 P323L
024 2270		Dfines	not	-	41-50	22.46	FDI 101 4022004	NV(111/4/220		0447	Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike N148T, Spike P681H, Spike S982A, Spike T716I, Spike V70del, Spike Y14del, N D3L, N G204R, N R203K, N S235F, NS3 L15F, NS8 G8R, NS8 Q27stop, NS8 R52J, NS8 Y73C, NSP3 A880D, NSP3 S126L, NSP3 T183I, NSP4 F17L, NSP6 F108del,
P21-2379	65	Pfizer	hospitalized	F	21-30	22.16	EPI_ISL_1922864	NYULH1628	GR	B.1.1.7	NSP6 G10/dei, NSP6 S106dei, NSP12 P323L, NSP13 K460R Spike A701V, Spike D253G, Spike D614G, Spike E484K, Spike Q1201L, Spike T95I, N M234I, N P199L,
P21-1403	72	Pfizer	not hospitalized	F		27.17	EPI_ISL_1532731	NYULH1080	GH	B.1.526	NS3 A335, NS3 P42L, NS3 Q57H, NS8 T11I, NSP2 T85I, NSP3 T1189I, NSP4 L438P, NSP4 S218F, NSP6 F108del, NSP6 G107del, NSP6 S106del, NSP12 P323L, NSP13 Q88H, NSP16 L163F
P21-1404	73	Pfizer	not hospitalized	F	41-50	16.63	EPI_ISL_1532746	NYULH1081	GRY	B.1.1.7	Spike A5700, Spike D614G, Spike D1118H, Spike H69del, Spike L5F, Spike N501Y, Spike P681H, Spike S982A, Spike T716i, Spike V70del, Spike Y144del, N O3L, N G204R, N R203K, N S235F, NS3 T1511, NS7a G62stop, NS8 Q27stop, NS8 R521, NS8 Y73C, NSP2 L137F, NSP3 A890D, NSP3 11412T, NSP3 P340U, NSP3 T1831, NSP3 T13031, NSP6 F108del, NSP6 G107del, NSP6 S106del, NSP12 P323L, NSP12 T7391
P21-2380	70	Pfizer	not hospitalized	м	31-40	32.53	EPI ISI 1922865	NYULH1629	GH	B.1.526.1	Spike D80G, Spike D614G, Spike D950H, Spike F157S, Spike L452R, Spike T859N, Spike Y144del, N M234I, N T205I, N53 P42L, N53 Q57H, NS8 A515, NS8 F3L, NS8 T311, NSP2 T85I, NSP4 A446V, NSP4 K399E, NSP4 L438P, NSP5 P96S, NSP6 F108del, NSP6 G107del, NSP6 S106del, NSP6 V278I, NSP12 P323I, NSP14 V398I
024 4262		Dfiner	not	-	41-50	40.04		NV(1) 1/4 0 C4	<u>au</u>	D 4 526 4	Spike D80G, Spike D614G, Spike D950H, Spike F157S, Spike L452R, Spike T323J, Spike T676J, Spike T859N, Spike Y144del, N M234J, N T205J, NS3 P42L, NS3 P104L, NS3 Q57H, NS8 A51S, NS8 T11J, NSP2 T85J, NSP3 A861S, NSP4 A446V, NSP4 L438P, NSP6 F108del, NSP6 G107del, NSP6 S106del, NSP6 L537D, NSP3 A932D, NSP6 C4060
P21-1362	61	Pfizer	nospitalized	F	71-80	19.94	EPI_ISL_1532753	NYULH1061	GH	B.1.526.1	Spike A570D, Spike D614G, Spike D1118H, Spike P681H, Spike S982A, Spike T716I, N D3L, N G204R,
P21-1595	53	Pfizer	not hospitalized	F		17.6	EPI_ISL_1576946	NYULH1178	GR	B.1.1.7	N R203K, N S235F, NS8 T111, NSP2 L550F, NSP3 A890D, NSP3 I1412T, NSP6 F108del, NSP6 G107del, NSP6 S106del, NSP12 P323L
P21-1415	42	Moderna	not hospitalized	м	61-70	23.61	EPI ISI 1532745	NYULH1088	GRY	B.1.1.7	Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike N501Y, Spike P681H, Spike S982A, Spike T716I, Spike V70del, Spike Y144del, N D3L, N G204R, N R203K, N S235F, NS3 P240S, NS8 K685top, NS8 Q27stop, NS8 R52I, NS8 Y73C, NSP3 A890D, NSP3 E95D, NSP3 I1412T, NSP3 M1441I, NSP3 T183L NSP6 F1084del, NSP6 G107del, NSP6 S106del, NSP1 29731, NSP13 T588L
D24 4550	05	Dfiner	not		41-50	40.62		NW411144220	<u>au</u>	0.4.526.2	Spike D253G, Spike D614G, Spike L5F, Spike Q957R, Spike S477N, Spike T95I, N A414V, N P13L, N S202R, NS3 P42L, NS3 Q57H, NS7a L116F, NS8 T111, NSP2 T85I, NSP3 A1179T, NSP3 G1128S, NSP3 T1022I, NSP4 L438P, NSP4 T319I, NSP6 F108del, NSP6 G107del, NSP6 S106del, NSP12 P323L, NSP13
P21-1550	65	Plizer	nospitalizeu	IVI	81-90	16.02	EPI_ISL_1370907	NTULH1159	ы	B.1.520.2	U0000 Calka AE70D, Salka DC14C, Salka D1119U, Salka US0dal, Salka DS01U, Salka S002A, Salka T715U
P21-1993	50	Moderna	Hospitalized for COVID	м		22.85	EPI_ISL_1669821	NYULH1262	GR	B.1.1.7	Spike V70del, Spike V14del, N D3L, N G204R, N R203K, N S235F, NS3 P240S, NS4 F1716, Spike V70del, Spike V14del, N D3L, N G204R, N R203K, N S235F, NS3 P240S, NS3 T9I, NS8 K68stop, NS8 Q275top, NS8 R521, NS8 Y73C, NSP A8900, NSP3 E950, NSP3 K963R, NSP3 M14411, NSP3 T1831, NSP6 F108del, NSP6 G107del, NSP6 S106del, NSP12 P227L, NSP12 P323L, NSP16 A34V
P21-2384	50	Moderna	not hospitalized	F	71-80	24.49	EPI ISL 1922869	NYULH1633	GRY	B.1.1.7	Spike A570D, Spike D514G, Spike D1118H, Spike H69del, Spike N501Y, Spike F681H, Spike S982A, Spike T716J, Spike V70del, Spike Y144del, N D3L, N G204R, N R203X, N S235F, NS3 P240S, NS8 K68stop, NS8 Q27stop, NS8 R52I, NS8 Y73C, NSP3 A890D, NSP3 E95D, NSP3 I1412T, NSP3 K963R, NSP3 M14411, NSP3 T183I, NSP6 F108del, NSP6 G107del, NSP6 G107del, NSP12 P327J, NSP12 P323L
			not		71-80						Snike A570D, Snike D614G, Snike P681H, N D3L, N G204R, N R203K, NS8 A515, NS8 T11L NSP6
P21-1596	57	Moderna	hospitalized	м		33.8	EPI_ISL_1576948	NYULH1179	GR	B.1.1	F108del, NSP6 G107del, NSP6 S106del
P21-2191	68	Pfizer	not hospitalized	м	31-40	17.86	EPI_ISL_1790045	NYULH1414	GH	B.1.526	Spike D614G, N M234I, N P168S, N P199L, NS3 P42L, NS3 Q57H, NS8 T11I, NSP2 T85I, NSP4 L438P, NSP5 P241S, NSP6 F108del, NSP6 G107del, NSP6 S106del, NSP12 P323L, NSP13 G54C
P21-2192	23	Janssen (J&J)	Hospitalized	м	41-50	25.25	EPI ISL 1790046	NYULH1415	GR	B.1.1.7	Spike A570D, Spike D614G, Spike P681H, Spike T716I, N D3L, N G204R, N R203K, N S235F, NS8 K68stop, NS8 Q27stop, NS8 Y73C, NSP6 R138del, NSP6 V139del, NSP6 V140del
		(100)	hospitalized but not for		71-80	15.15					Spike A5700, Spike D5146, Spike D5118H, Spike H69del, Spike K1191N, Spike N501Y, Spike P681H, Spike S982A, Spike T716I, Spike V70del, Spike Y144del, N D3L, N G204R, N R203K, N S235F, NS8 Q27stop, NS8 R52J, NS8 Y73C, NS79 A252V, NS79 A3900, NS79 11432I, NS79 11381, NS76 F108del,
P21-2738	49	Moderna	covid	М	24.20	28.14	EPI_ISL_2400287	NYULH1814	GRY	B.1.1.7	NSP6 G107del, NSP6 S106del, NSP8 Q24R, NSP12 P323L, NSP13 K460R, NSP14 D324E, NSP16 K160R
P21-1574	22	Pfizer	not hospitalized	F	21-30	23.28	EPI ISL 1576925	NYULH1157	G	B.1	эріке иглэд, эріке иb14д, эріке s47 /N, эріке 1951, N GZU4R, N RZU3K, N SZ35F, NS3 P42L, NS3 Q57H, NS8 T11I, NSP2 T851, NSP3 G1128S, NSP4 L438P, NSP6 F108del, NSP6 G107del, NSP6 S106del, NSP12 P323L, NSP13 Q88H

					21-30						Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike N501Y, Spike P681H, Spike S982A,
											Spike T716I, Spike V70del, Spike Y144del, M G89S, N A398V, N D3L, N G204R, N R203K, N S235F,
P21-1985	76	Pfizor	not	м		22.74	ERI ISI 1654640	NVIII H1248	GRV	B117	NS3 L15F, NS8 Q2/stop, NS8 R52I, NS8 Y/3C, NSP3 A890D, NSP3 I1412T, NSP3 I183I, NSP4 F1/L, NSP6 F108dol, NSP6 G107dol, NSP6 S106dol, NSP8 O73K, NSP12 P3231, NSP13 K/60P
F21-1985	70	FIIZEI	nospitalizeu	IVI	71-80	22.74	LFI_13L_1034040	NTOLITI248	GKT	B.1.1.7	Snike A7011/ Snike D253G Snike D614G Snike F484K Snike T05LN M234LN D100L NS3 P42L NS3
			not		/100						Q57H, NS8 T11I, NSP2 T85I, NSP4 L438P, NSP6 F108del, NSP6 G107del, NSP6 S106del, NSP12 P323L
P21-2370	48	Pfizer	hospitalized	м		31.20	EPI_ISL_1922857	NYULH1620	GH	B.1.526	NSP13 Q88H
					51-60						Spike D253G, Spike D614G, Spike L5F, Spike Q957R, Spike S477N, Spike T95I, N P13L, N S202R, NS3
			not								P42L, NS3 Q57H, NS7a L116F, NS7b H37L, NS8 T11I, NSP2 T85I, NSP2 T434I, NSP3 G1128S, NSP4
P21-1984	75	Pfizer	hospitalized	М		27.03	EPI_ISL_1654639	NYULH1247	GH	B.1.526.2	L438P, NSP6 F108del, NSP6 G107del, NSP6 S106del, NSP12 P323L, NSP13 Q88H
					31-40						Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike N501Y, Spike P681H, Spike S982A,
			not								Spike 1/10i, Spike V/Odel, Spike 1144del, N DSL, N G204R, N R205R, N S255F, NS5 A991, NS5 V90F,
P21-1970	71	Moderna	hospitalized	F		21.63	EPI ISL 1669802	NYULH1260	GRY	B.1.1.7	F108del, NSP6 G107del, NSP6 S106del, NSP12 P323L, NSP13 K460R, NSP14 E347G
					31-40						Spike D80G, Spike D614G, Spike D950H, Spike F157S, Spike L452R, Spike S155R, Spike T859N, Spike
											Y144del, N M234I, N T205I, NS3 P42L, NS3 P104L, NS3 Q57H, NS8 A51S, NS8 T11I, NSP2 T85I, NSP3
			not								A861S, NSP4 A446V, NSP4 K399E, NSP4 L438P, NSP6 F108del, NSP6 G107del, NSP6 S106del, NSP6
P21-1976	89	Pfizer	hospitalized	м		19.36	EPI_ISL_1669803	NYULH1261	GH	B.1.526.1	V278I, NSP12 P323L, NSP12 T806I, NSP13 T239I
					41-50						Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike P681H, Spike S982A, Spike 1716I, Spike V70del, Spike V144del N C204P, N D202K, N C22EE, NS8 SC7E, NS8 T111, NSD1 N178S, NSD2
			not								1550E, NSP3 A890D, NSP3 11412T, NSP3 T1831, NSP6 F108del, NSP6 G107del, NSP6 S106del, NSP1
P21-1992	76	Pfizer	hospitalized	м		20.54	EPI ISL 1654647	NYULH1255	GR	B.1.1.7	P323L, NSP13 Q88H
					51-60						Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike N501Y, Spike P681H, Spike S982A,
											Spike T716I, Spike V70del, Spike Y144del, M G89S, N A398V, N D3L, N G204R, N R203K, N S235F,
			not								NS3 L15F, NS8 Q27stop, NS8 R52I, NS8 Y73C, NSP3 A890D, NSP3 I1412T, NSP3 T183I, NSP4 F17L,
P21-1964	78	Pfizer	hospitalized	м		32.91	EPI_ISL_1669801	NYULH1259	GRY	B.1.1.7	NSP6 F108del, NSP6 G107del, NSP6 S106del, NSP8 Q73K, NSP12 P323L, NSP13 K460R
					51-60						Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike N501Y, Spike P681H, Spike S98ZA,
			not								O27stop, NS8 R52L NS8 Y73C, NSP3 A890D, NSP3 I310T, NSP3 I1412T, NSP3 M1441L NSP3 P108L
P21-2385	72	Pfizer	hospitalized	м		29.35	EPI_ISL_1922870	NYULH1634	GRY	B.1.1.7	NSP3 T183I, NSP6 F108del, NSP6 G107del, NSP6 S106del, NSP12 P227L, NSP12 P323L
					31-40						
			not	_							Spike D614G, Spike P681H, Spike T678I, Spike T716I, M I82T, N T205I, NS3 Q57H, NS7a L96F, NSP4
P21-2096	88	Pfizer	hospitalized	F	71.90	33.12	EPI_ISL_1789975	NYULH1340	GH	B.1.575	T492I, NSP6 T181I, NSP12 P323L, NSP13 T127I, NSP15 L162V
			hospitalized		/1-80						Spike AS70D, Spike D0140, Spike D1110H, Spike H09del, Spike K1191N, Spike NS01T, Spike P001H, Spike S082A, Spike T716L Spike V70del, Spike V14/del, N D3L, N G204R, N R203K, N S235E, NS8
			but not for								Q27stop, NS8 R52I, NS8 Y73C, NSP3 A225V, NSP3 A890D, NSP3 I1412T, NSP3 T183I, NSP6 F108del.
P21-2080	60	Moderna	covid	м		24.18	EPI_ISL_1789962	NYULH1325	GRY	B.1.1.7	NSP6 G107del, NSP6 S106del, NSP8 Q24R, NSP12 P323L, NSP13 K460R, NSP14 D324E, NSP16 K160R
					41-50						Spike D614G, Spike H655Y, Spike K417T, Spike T1027I, Spike V1176F, N G204R, N P80R, N R203K,
			not								NS3 S253P, NS8 E92K, NSP3 K977Q, NSP3 P822S, NSP6 F108del, NSP6 G107del, NSP6 K4R, NSP6
P21-2193	94	Pfizer	hospitalized	F	54.60	24.51	EPI_ISL_1790047	NYULH1416	GR	P.1	S106del, NSP12 P94L, NSP12 P323L, NSP13 E341D, NSP14 A119V
					51-60						Spike AS70D, Spike D614G, Spike D1118H, Spike H69del, Spike P681H, Spike S982A, Spike 1716i, Spike V70del Spike Y144del N D3L N G204R N R203K N S235F NS8 K68ston NS8 O27ston NS8
			not								R52I, NS8 Y73C, NSP3 A890D, NSP3 I1412T, NSP3 T183I, NSP3 T1127I, NSP6 F108del, NSP6 G107del,
P21-2364	59	Pfizer	not hospitalized	м		31.03	EPI_ISL_1922853	NYULH1616	GR	B.1.1.7	R521, NS8 Y73C, NSP3 A890D, NSP3 I1412T, NSP3 T183I, NSP3 T1127I, NSP6 F108del, NSP6 G107del, NSP6 S106del, NSP12 P227L, NSP12 P323L, NSP14 P451S
P21-2364	59	Pfizer	not hospitalized	м	61-70	31.03	EPI_ISL_1922853	NYULH1616	GR	B.1.1.7	R52I, NS8 Y73C, NSP3 A890D, NSP3 11412T, NSP3 T183I, NSP3 T1127I, NSP6 F108del, NSP6 G107del, NSP6 S106del, NSP12 P227L, NSP12 P323L, NSP14 P451S
P21-2364	59	Pfizer	not hospitalized not	м	61-70	31.03	EPI_ISL_1922853	NYULH1616	GR	B.1.1.7	R52I, NS8 Y73C, NSP3 A890D, NSP3 11412T, NSP3 T183I, NSP3 T1127I, NSP6 F108del, NSP6 G107del, NSP6 S106del, NSP12 P227L, NSP12 P323L, NSP14 P451S Spike A222V, Spike D614G, Spike G769V, Spike S255F, N G204R, N Q418H, N R203K, N S187L, NSP2 A206V, NSP3 S165EA, NG21 A023L, NSP3C A208A, D812H, D812H
P21-2364 P21-2378	59 20	Pfizer Pfizer	not hospitalized not hospitalized	м	61-70	31.03 25.32	EPI_ISL_1922853 EPI_ISL_1922863	NYULH1616 NYULH1627	GR GR	B.1.1.7 B.1.1	R52I, NS8 Y73C, NSP3 A890D, NSP3 11412T, NSP3 T183I, NSP3 T1127I, NSP6 F108del, NSP6 G107del, NSP6 5106del, NSP12 P227L, NSP12 P323L, NSP14 P451S Spike A222V, Spike D614G, Spike G769V, Spike S255F, N G204R, N Q418H, N R203K, N 5187L, NSP2 A306V, NSP3 51656A, NSP12 P323L, NSP13 G439R, NSP14 P412H
P21-2364 P21-2378	59 20	Pfizer Pfizer	not hospitalized not hospitalized	м	61-70 61-70	31.03 25.32	EPI_ISL_1922853 EPI_ISL_1922863	NYULH1616 NYULH1627	GR GR	B.1.1.7 B.1.1	R52I, NS8 Y73C, NSP3 A890D, NSP3 I1412T, NSP3 T183I, NSP3 T1127I, NSP6 F108del, NSP6 G107del, NSP6 S106del, NSP12 P227L, NSP12 P323L, NSP14 P451S Spike A222V, Spike D614G, Spike G769V, Spike S255F, N G204R, N Q418H, N R203K, N S187L, NSP2 A306V, NSP3 S1656A, NSP12 P323L, NSP13 G439R, NSP14 P412H Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike P681H, Spike S982A, Spike T716I, Spike Y70del, Spike Y14del, N D3L, N G204R, N R203K, N S235F, NS8 C61F, NS8 K68stoo. NS8
P21-2364 P21-2378	59 20	Pfizer Pfizer	not hospitalized not hospitalized not	м	61-70 61-70	31.03 25.32	EPI_ISL_1922853 EPI_ISL_1922863	NYULH1616 NYULH1627	GR GR	B.1.1.7 B.1.1	R52I, NS8 Y73C, NSP3 A890D, NSP3 11412T, NSP3 T183I, NSP3 T1127I, NSP6 F108del, NSP6 G107del, NSP6 S106del, NSP12 P227L, NSP12 P323L, NSP14 P451S Spike A222V, Spike D614G, Spike G769V, Spike S255F, N G204R, N Q418H, N R203K, N S187L, NSP2 A306V, NSP3 S1656A, NSP12 P323L, NSP13 G439R, NSP14 P412H Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike P681H, Spike S982A, Spike T716I, Spike V70del, Spike Y144del, N D3L, N G204R, N R203K, N S235F, NS8 C61F, NS8 K68stop, NS8 Q27stop, NS8 R52J, NS8 Y73C, NSP3 A800D, NSP6 F108del, NSP6 1207
P21-2364 P21-2378 P21-2382	59 20 26	Pfizer Pfizer Pfizer	not hospitalized not hospitalized not hospitalized	м м м	61-70	31.03 25.32 18.13	EPI_ISL_1922853 EPI_ISL_1922863 EPI_ISL_1922867	NYULH1616 NYULH1627 NYULH1631	GR GR GR	B.1.1.7 B.1.1 B.1.1.7	R52I, NS8 Y73C, NSP3 A890D, NSP3 11412T, NSP3 T183I, NSP3 T1127I, NSP6 F108del, NSP6 G107del, NSP6 S106del, NSP12 P27ZL, NSP12 P323L, NSP14 P451S Spike A222V, Spike D614G, Spike G769V, Spike S255F, N G204R, N Q418H, N R203K, N S187L, NSP2 A306V, NSP3 S1656A, NSP12 P323L, NSP13 G439R, NSP14 P412H Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike P681H, Spike S982A, Spike T716I, Spike V70Del, Spike V144del, N D3L, N G204R, N R203K, N S235F, NS8 C61F, NS8 K68stop, NS8 Q27stop, NS8 R52I, NS8 Y73C, NSP3 A890D, NSP6 F108del, NSP6 G107del, NSP6 S106del, NSP12 P227L, NSP12 P323L
P21-2364 P21-2378 P21-2382	59 20 26	Pfizer Pfizer Pfizer	not hospitalized not hospitalized not hospitalized	M M M	61-70 61-70 21-30	31.03 25.32 18.13	EPI_ISL_1922853 EPI_ISL_1922863 EPI_ISL_1922867	NYULH1616 NYULH1627 NYULH1631	GR GR GR	B.1.1.7 B.1.1 B.1.1.7	R521, NS8 Y73C, NSP3 A890D, NSP3 11412T, NSP3 T1831, NSP3 T11271, NSP6 F108del, NSP6 G107del, NSP6 5106del, NSP12 P227L, NSP12 P323L, NSP14 P451S Spike A222V, Spike D614G, Spike G769V, Spike 5255F, N G204R, N Q418H, N R203K, N 5187L, NSP2 A306V, NSP3 51656A, NSP12 P323L, NSP13 G439R, NSP14 P412H A906V, NSP3 51656A, NSP12 P323L, NSP13 G439R, NSP14 P412H Spike A570D, Spike D614G, Spike D118H, Spike H508, DSike P681H, Spike 5982A, Spike T716I, Spike V70del, Spike Y144del, N D3L, N G204R, N R203K, N S235F, NS8 C61F, NS8 K68stop, NS8 Q27stop, NS8 R52I, NS8 Y73C, NSP3 A890D, NSP6 F108del, NSP6 G107del, NSP6 S106del, NSP12 P272L, NSP12 P3231 Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike N501Y, Spike P681H, Spike S982A,
P21-2364 P21-2378 P21-2382	59 20 26	Pfizer Pfizer Pfizer	not hospitalized not hospitalized not hospitalized	м м м	61-70 61-70 21-30	31.03 25.32 18.13	EPI_ISL_1922853 EPI_ISL_1922863 EPI_ISL_1922867	NYULH1616 NYULH1627 NYULH1631	GR GR GR	B.1.1.7 B.1.1 B.1.1.7	R52I, NS8 Y73C, NSP3 A890D, NSP3 11412T, NSP3 1183I, NSP3 11127I, NSP6 F108del, NSP6 G107del, NSP6 S106del, NSP12 P227L, NSP12 P323L, NSP14 P451S Spike A222V, Spike D614G, Spike G769V, Spike S255F, N G204R, N Q418H, N R203K, N S187L, NSP2 A306V, NSP3 S1656A, NSP12 P323L, NSP13 G439R, NSP14 P412H Spike A570D, Spike D614G, Spike D118H, Spike H69del, Spike P681H, Spike S982A, Spike 716I, Spike V70del, Spike Y144del, N D3L, N G204R, N R203K, N S235F, NS8 C61F, NS8 K68stop, NS8 Q27stop, NS8 R52I, NS8 V73C, NSP3 A890D, NS9F 61208del, NSP6 G107del, NSP6 5106del, NSP12 P327L, NSP12 P323L Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike N501Y, Spike P681H, Spike S982A, Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike N501Y, Spike P681H, Spike S982A, Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike N501Y, Spike P681H, Spike S982A, Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike N501Y, Spike P681H, Spike S982A, Spike A570D, Spike D614G, Spike V144del, N D3L, N 6204R, N R14C, N R203K, N 5235F, NS8 K68top, NS8 0737ch, NS8 K52J, NS8 K72G, NS8 400D, NS8 11411, NS8P1 K131, NF65 51040H, NS74, NS74A, NS74, NS74A, NS74
P21-2364 P21-2378 P21-2382 P21-2105	59 20 26 97	Pfizer Pfizer Pfizer	not hospitalized not hospitalized not hospitalized	м м м	61-70 61-70 21-30	31.03 25.32 18.13 20.16	EPI_ISL_1922853 EPI_ISL_1922863 EPI_ISL_1922867 EPI_ISL_2202770	NYULH1616 NYULH1627 NYULH1631	GR GR GR	B.1.1.7 B.1.1 B.1.1.7	R52I, NS8 Y73C, NSP3 A890D, NSP3 11412T, NSP3 T183I, NSP3 T1127I, NSP6 F108del, NSP6 G107del, NSP6 S106del, NSP12 P22T, NSP12 P323I, NSP14 P451S Spike A222V, Spike D614G, Spike G769V, Spike S255F, N G204R, N Q418H, N R203K, N S187L, NSP2 A306V, NSP3 S1656A, NSP12 P323I, NSP13 G439R, NSP14 P412H Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike P681H, Spike S982A, Spike T716I, Spike X770, Spike D614G, Spike D1118H, Spike H69del, Spike P681H, Spike S982A, Spike T716I, Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike P681H, Spike S982A, Spike T716I, Spike A570D, Spike D614G, Spike D1118H, Spike H69del, NSP6 G107del, NSP6 S106del, NSP12 P227L, NSP12 P323L Spike A570D, Spike D614G, Spike 1118H, Spike H69del, Spike N501Y, Spike P681H, Spike S982A, Spike T716I, Spike V70del, Spike V144del, N D3L, N G204R, N R14C, N R203K, N S235F, NS8 K68stop, NS8 Q27stop, NS8 R52J, NS8 Y73C, NSP3 A890D, NSP3 11412T, NSP3 T183J, NSP6 F108del, NSP6 G107del, NSP6 F108L NSP6 S106del, NSP6
P21-2364 P21-2378 P21-2382 P21-2382 P21-2105	59 20 26 97	Pfizer Pfizer Pfizer	not hospitalized not hospitalized not hospitalized	м м м	61-70 61-70 21-30 21-30	31.03 25.32 18.13 20.16	EPI_ISL_1922853 EPI_ISL_1922863 EPI_ISL_1922867 EPI_ISL_2202770	NYULH1616 NYULH1627 NYULH1631 NYULH1344	GR GR GR GRY	B.1.1.7 B.1.1 B.1.1.7 B.1.1.7	R52I, NS8 Y73C, NSP3 A890D, NSP3 11412T, NSP3 T183I, NSP3 T1127I, NSP6 F108del, NSP6 G107del, NSP6 S106del, NSP12 P22T, NSP12 P323L, NSP14 P451S Spike A222V, Spike D614G, Spike G769V, Spike S255F, N G204R, N Q418H, N R203K, N S187L, NSP2 A306V, NSP3 S1656A, NSP12 P323L, NSP13 G439R, NSP14 P412H Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike P681H, Spike S982A, Spike T716I, Spike V70del, Spike V144del, N D3L, N G204R, N R203K, N S235F, NS8 C61F, NS8 K68stop, NS8 Q27stop, NS8 R52I, NS8 Y3C, NSP3 A890D, NSP6 F108del, NSP6 G107del, NSP6 S106del, NSP12 P227L, NSP12 P323L Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike NS01Y, Spike P681H, Spike S982A, Spike T716I, Spike V70del, Spike V144del, N D3L, N G204R, N R14C, N R203K, N S235F, NS8 K68stop, NS8 Q27stop, NS8 R52I, NS8 Y3C, NSP3 A890D, NSP3 11412T, NSP3 T183I, NSP6 F108del, NSP6 G107del, NSP6 P198L, NSP6 S106del, NSP12 P227L, NSP12 P323L Spike A570D, Spike D514G, Spike V144del, N D3L, N G204R, N R14C, N R205K, N S235F, NS8 K68stop, NS8 Q27stop, NS8 R52I, NS8 Y3C, NSP3 A890D, NSP3 11412T, NSP3 T183I, NSP6 F108del, NSP6 G107del, NSP6 P198L, NSP6 S106del, NSP12 P227L, NSP12 P323L
P21-2364 P21-2378 P21-2382 P21-2382	59 20 26 97	Pfizer Pfizer Pfizer Pfizer	not hospitalized not hospitalized not hospitalized not hospitalized not	м м м	61-70 61-70 21-30 21-30	31.03 25.32 18.13 20.16	EPI_ISL_1922853 EPI_ISL_1922863 EPI_ISL_1922867 EPI_ISL_2202770	NYULH1616 NYULH1627 NYULH1631 NYULH1344	GR GR GR GRY	B.1.1.7 B.1.1 B.1.1.7 B.1.1.7	R521, NS8 Y73C, NSP3 A890D, NSP3 11412T, NSP3 T1831, NSP3 T11271, NSP6 F108del, NSP6 G107del, NSP6 S106del, NSP12 P22T, NSP12 P323L, NSP14 P451S Spike A222V, Spike D614G, Spike G769V, Spike S255F, N G204R, N Q418H, N R203K, N S187L, NSP2 A306V, NSP3 S1656A, NSP12 P323L, NSP13 G439R, NSP14 P412H Spike A7200, Spike D614G, Spike D118H, Spike H69del, Spike P681H, Spike S982A, Spike T716I, Spike A700, Spike D514G, Spike D118H, Spike H69del, Spike P681H, Spike S982A, Spike T716I, Spike A700, Spike D514G, Spike D1118H, Spike H69del, Spike P681H, Spike S982A, Spike A570D, Spike D514G, Spike D118H, Spike H69del, Spike N501Y, Spike P681H, Spike S982A, Spike A7700, Spike D514G, Spike D118H, Spike H69del, Spike N501Y, Spike P681H, Spike S982A, Spike A7700, Spike D514G, Spike D118H, Spike H69del, NP66 S104C, N R203K, N S235F, NS8 K68stop, Ssige T716I, Spike V70del, Spike D118H, Spike H69del, Spike N501Y, Spike P681H, Spike S982A, Spike A7700, Spike D514G, Spike D146, Spike P118H, NP14L, N53 11412T, NS97 F1183I, NSP6 F108del, NSP6 Spike A7700, Spike D513G, Spike D51464L, N5212 P227L, NSP12 P232L Spike A701V, Spike D523G, Spike D514G51, NSP12 P227L, NSP12 P232L Spike A701V, Spike D533G, Spike D614G, Spike T951, NM2341, N 1919L, NS3 P42L, NS4 F4386S, NSP6 F108del, NSP6 6107del,
P21-2364 P21-2378 P21-2382 P21-2105 P21-2372	59 20 26 97 66	Pfizer Pfizer Pfizer Pfizer	not hospitalized not hospitalized not hospitalized not hospitalized	м м м	61-70 61-70 21-30 21-30	31.03 25.32 18.13 20.16 20.61	EPI_ISL_1922853 EPI_ISL_1922863 EPI_ISL_1922867 EPI_ISL_2202770 EPI_ISL_1922859	NYULH1616 NYULH1627 NYULH1631 NYULH1344 NYULH1622	GR GR GR GRY GH	B.1.1.7 B.1.1 B.1.1.7 B.1.1.7 B.1.526	F521, NS8 Y73C, NSP3 A890D, NSP3 11412T, NSP3 T1831, NSP3 T11271, NSP6 F108del, NSP6 G107del, NSP6 S106del, NSP12 P227L, NSP12 P323L, NSP14 P451S Spike A222V, Spike D614G, Spike G769V, Spike S255F, N G204R, N Q418H, N R203K, N S187L, NSP2 A306V, NSP3 S1656A, NSP12 P323L, NSP14 P451S Spike A570D, Spike D614G, Spike G769V, Spike S255F, N G204R, N Q418H, N R203K, N S187L, NSP2 A306V, NSP3 S1656A, NSP12 P323L, NSP14 P412H Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike P681H, Spike S982A, Spike T716I, Spike X70del, Spike V144del, N D3L, N G204R, N R203K, N S235F, NS8 C61F, NS8 K68stop, NS8 Q27stop, NS8 R52J, NS8 Y73C, NSP3 A800D, NSP6 F108del, Spike N501Y, Spike P681H, Spike S982A, Spike X70del, Spike V144del, N D3L, N G204R, N R14C, N R203K, N S235F, NS8 K68stop, NS8 Q27stop, NS8 R52J, NS8 Y73C, NSP3 A800D, NSP6 F108del, Spike N501Y, Spike P681H, Spike S982A, Spike X70del, Spike D1118H, Spike H69del, Spike N501Y, Spike P681H, Spike S982A, Spike X716J, Spike V70del, Spike Y144del, N D3L, N G204R, N R14C, N R203K, N S235F, NS8 K68stop, NS8 Q27stop, NS8 R52J, NS8 Y73C, NSP3 A890D, NSP3 11412T, NSP3 T183J, NSP6 F108del, NSP6 Spike A701V, Spike D536S, Spike D614G, Spike T95L N M234I, N P199L, NS3 P42I, NS3 P104L, NS3 Q57H, NS8 T11I, NSP2 A386S, NSP2 T85I, NSP3 S1588L, NSP4 L438P, NSP6 F108del, NSP6 G107del, NSP6 S106del, NSP2 A386S, NSP2 T85I, NSP3 S1588L, NSP4 L438P, NSP6 F108del, NSP6 G107del,
P21-2364 P21-2378 P21-2382 P21-2105 P21-2372	59 20 26 97 66	Pfizer Pfizer Pfizer Pfizer	not hospitalized not hospitalized not hospitalized not hospitalized	м м м м	61-70 61-70 21-30 21-30 31-40	31.03 25.32 18.13 20.16 20.61	EPI_ISL_1922853 EPI_ISL_1922863 EPI_ISL_1922867 EPI_ISL_1922867 EPI_ISL_2202770 EPI_ISL_1922859	NYULH1616 NYULH1627 NYULH1631 NYULH1344 NYULH1622	GR GR GR GRY GH	B.1.1.7 B.1.1 B.1.1.7 B.1.1.7 B.1.526	R52I, NS8 Y73C, NSP3 A890D, NSP3 11412T, NSP3 T183I, NSP3 T1127I, NSP6 F108del, NSP6 G107del, NSP6 S106del, NSP12 P227L, NSP12 P323L, NSP14 P451S Spike A222V, Spike D614G, Spike G769V, Spike S255F, N G204R, N Q418H, N R203K, N S187L, NSP2 A306V, NSP3 S1656A, NSP12 P323L, NSP14 G439R, MSP14 P412H Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike P681H, Spike S982A, Spike T716i, Spike K770d, Spike D614G, Spike D1118H, Spike H69del, Spike P681H, Spike S982A, Spike T716i, Spike K770D, Spike D614G, Spike D1118H, Spike H69del, Spike P681H, Spike S982A, Spike K570D, Spike D614G, Spike D1118H, Spike H69del, Spike P681H, Spike S982A, Spike T51, NS8 Y73C, NS93 A890D, NSP6 F108del, NSP6 G107del, NSP6 S106del, NSP12 P227L, NSP12 P323L Spike K570D, Spike D614G, Spike D1118H, Spike H69del, Spike N501Y, Spike P681H, Spike S982A, Spike T51, NS8 Y73C, NSP3 A890D, NSP3 11412T, NSP3 T183I, NSP6 F108del, NSP6 G107del, NSP6 P198L, NSP6 S106del, NSP12 P227L, NSP12 P323L Spike A5701Y, Spike D536, Spike D614G, Spike T951, N M234I, N P199L, NS3 P42L, NS3 P104L, NS3 Q37+N, NS8 T11, NSP2 A386S, NSP2 T851, NSP3 S188L, NSP4 L438P, NSP6 F108del, NSP6 G107del, NSP6 G1036, Spike D6446, Spike Z484K, Spike L5F, Spike T951, N M234I, N P199L, NS3
P21-2364 P21-2378 P21-2382 P21-2105 P21-2105 P21-2372	59 20 26 97 66	Pfizer Pfizer Pfizer Pfizer Pfizer	not hospitalized not hospitalized not hospitalized not hospitalized not hospitalized	M M M M	61-70 61-70 21-30 21-30 31-40	31.03 25.32 18.13 20.16 20.61	EPI_ISL_1922853 EPI_ISL_1922863 EPI_ISL_1922867 EPI_ISL_2202770 EPI_ISL_2202770 EPI_ISL_1922859 EPI_ISL_1922859	NYULH1616 NYULH1627 NYULH1631 NYULH1344 NYULH1324	GR GR GR GRY GH	B.1.1.7 B.1.1 B.1.1.7 B.1.1.7 B.1.526	R52I, NS8 Y73C, NSP3 A890D, NSP3 11412T, NSP3 T183I, NSP3 T1127I, NSP6 F108del, NSP6 G107del, NSP6 S106del, NSP12 P22T, NSP12 P323L, NSP14 P451S Spike A222V, Spike D614G, Spike G769V, Spike S255F, N G204R, N Q418H, N R203K, N S187L, NSP2 A306V, NSP3 S1656A, NSP12 P323L, NSP13 G439R, NSP14 P412H Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike P681H, Spike S982A, Spike T716I, Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike P681H, Spike S982A, Spike T716I, Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike NSP6 5107del, NSP6 5106del, NSP12 P227L, NSP12 P323L Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike NS01Y, Spike P681H, Spike S982A, Spike T716I, Spike V70del, ND3H, NC204K, N R12C, NC30X, N S235F, NS8 K68stop, NS8 Q27stop, NS8 R52I, NS8 Y3C, NSP3 A890D, NSP6 F108del, NSP6 5103del, NSP6 5106del, NSP12 P227L, NSP12 P323L Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike NS01Y, Spike P681H, Spike S982A, Spike T710H, Spike V73del, NSP3 Spike V1440H, ND3L, NC204K, N R14C, N R203X, N S235F, NS8 K68stop, NS8 Q27stop, NS8 R52I, NS8 Y3C, NSP3 A890D, NSP3 11412T, NSP3 T183I, NSP6 F108del, NSP6 G107del, NSP6 P198L, NSP2 A3865, NSP2 T85I, NSP3 S1588L, NSP4 L438P, NSP6 F108del, NSP6 G107del, NSP6 S106del, NSP12 P323L, NSP1 308H Spike A701V, Spike D513G, Spike D614G, Spike E484K, Spike L5F, Spike T95I, N M234I, N P199L, NS3 P42L, NS3 Q57H, NS8 A65V, NS8 T11I, NSP2 T85I, NSP4 L438P, NSP6 F108del, NSP6 G107del, NSP6 S106del, NSP12 P332L, NSP1 308H
P21-2364 P21-2378 P21-2382 P21-2105 P21-2372 P21-2372	59 20 26 97 66 67	Pfizer Pfizer Pfizer Pfizer Pfizer Moderna	not hospitalized not hospitalized not hospitalized not hospitalized not hospitalized	м м м м	61-70 61-70 21-30 21-30 31-40 81-90	31.03 25.32 18.13 20.16 20.61 17.78	EPI_ISL_1922853 EPI_ISL_1922863 EPI_ISL_1922867 EPI_ISL_2202770 EPI_ISL_2202770 EPI_ISL_1790005	NYULH1616 NYULH1627 NYULH1631 NYULH1344 NYULH1374	GR GR GRY GH GH	B.1.1.7 B.1.1 B.1.1.7 B.1.1.7 B.1.526 B.1.526	R52I, NS8 Y73C, NSP3 A890D, NSP3 11412T, NSP3 T183I, NSP3 T1127I, NSP6 F108del, NSP6 G107del, NSP6 S106del, NSP12 P227L, NSP12 P323L, NSP14 P451S Spike A222V, Spike D614G, Spike G769V, Spike S255F, N G204R, N Q418H, N R203K, N S187L, NSP2 A306V, NSP3 S1656A, NSP12 P323L, NSP13 G439R, NSP14 P412H Spike A570D, Spike D614G, Spike D118H, Spike H69del, Spike P681H, Spike S982A, Spike 7176I, Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike P681H, Spike S982A, Spike 7176I, Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike N501Y, Spike S982A, Spike 7176I, Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike N501Y, Spike P681H, Spike S982A, Spike T716I, Spike Y144del, N D3L, N G204R, N D30A, N C204R, N R14C, N R203K, N S235F, NS8 K68stop, NS8 Q27stop, NS8 R521, NS8 Y73C, NSP3 A890D, NSP3 1142T, NSP3 T1831, NSP6 F108del, NSP6 Spike A701V, Spike D253G, Spike D614G, Spike T951, N M234I, N T199L, NS3 P42L, NS3 P104L, NS3 Spike A701V, Spike D253G, Spike D614G, Spike T951, N M234I, N T199L, NS3 P42L, NS3 P104L, NS3 Spike A701V, Spike D233G, Spike D614G, Spike E484K, Spike L5F, Spike T9108del, NSP6 G107del, NSP6 S106del, NSP12 P323L, SSP13 Q88H Spike A701V, Spike D233G, Spike D614G, Spike E484K, Spike L5F, Spike T9108del, NSP6 G107del, NSP6 S106del, NSP12 P323L, NSP13 Q88H Spike A701V, Spike D233G, Spike D614G, Spike E484K, Spike L5F, Spike T9108del, NSP4 S1036H, NSP6 S106del, NSP12 P323L, NSP13 Q88H Spike A701V, Spike D233G, Spike D614G, Spike T9
P21-2364 P21-2378 P21-2382 P21-2105 P21-2105 P21-2372 P21-2137	59 20 26 97 66 67	Pfizer Pfizer Pfizer Pfizer Pfizer Moderna	not hospitalized not hospitalized not hospitalized not hospitalized not hospitalized hospitalized	M M M F	61-70 61-70 21-30 21-30 31-40 81-90	31.03 25.32 18.13 20.16 20.61 17.78	EPI_ISL_1922853 EPI_ISL_1922863 EPI_ISL_1922867 EPI_ISL_2202770 EPI_ISL_2202770 EPI_ISL_1922859 EPI_ISL_1790005	NYULH1616 NYULH1627 NYULH1631 NYULH1344 NYULH1622 NYULH1374	GR GR GR GRY GH	B.1.1.7 B.1.1 B.1.1.7 B.1.526 B.1.526	S21, NS8 Y73C, NSP3 A890D, NSP3 11412T, NSP3 T1831, NSP3 T11271, NSP6 F108del, NSP6 G107del, NSP6 S106del, NSP12 P227L, NSP12 P323L, NSP14 P451S Spike A222V, Spike D614G, Spike G769V, Spike S255F, N G204R, N Q418H, N R203K, N S187L, NSP2 A306V, NSP3 S1656A, NSP12 P323L, NSP14 P451S Spike A222V, Spike D614G, Spike G769V, Spike S255F, N G204R, N Q418H, N R203K, N S187L, NSP2 A306V, NSP3 S1656A, NSP12 P323L, NSP14 P412H Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike P681H, Spike S982A, Spike T716i, Spike X70D, Spike D614G, Spike D1118H, Spike H69del, Spike NS01Y, Spike P681H, SPike S982A, Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike NS01Y, Spike P681H, Spike S982A, Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike NS01Y, Spike P681H, Spike S982A, Spike T716i, Spike V70del, Spike Y144del, N D3L, N G204R, N R14C, N R203K, N S235F, NS8 K68stop, S027stop, NS8 R521, NS8 Y73C, NSP3 A890D, NSP3 11412T, NSP3 T183I, NSP6 F108del, NSP6 Spike A701V, Spike D536S, Spike D614G, Spike T951, N M234I, N P199L, NS3 P412, NS3 P104L, NS3 Spike A701V, Spike D253G, Spike D614G, Spike T951, N M234I, N P191, NS3 P134L, NS9 6 107del, NSP6 Spic A701V, Spike D253G, Spike D614G, Spike E484K, Spike L5F, Spike T951, N M234I, N P199L, NS3 Spike A701V, Spike D253G, Spike D614G, Spike E484K, Spike L5F, Spike T951, N M234I, N P199L, NS3 Spike A701V, Spike D253G, Spike D614G, Spike E484K, Spike L5F, Spike T951, N M234I, N P
P21-2364 P21-2378 P21-2382 P21-2105 P21-2372 P21-2372 P21-2137	59 20 26 97 66 67	Pfizer Pfizer Pfizer Pfizer Pfizer Moderna	not hospitalized not hospitalized not hospitalized not hospitalized not hospitalized hospitalized bospitalized but not for	M M M M	61-70 61-70 21-30 21-30 31-40 81-90	31.03 25.32 18.13 20.16 20.61 17.78	EPI_ISL_1922853 EPI_ISL_1922863 EPI_ISL_1922867 EPI_ISL_2202770 EPI_ISL_1922859 EPI_ISL_1790005	NYULH1616 NYULH1627 NYULH1631 NYULH1344 NYULH1344 NYULH1374	GR GR GR GRY GH GH	B.1.1.7 B.1.1 B.1.1.7 B.1.1.7 B.1.526 B.1.526	R521, NS8 Y73C, NSP3 A890D, NSP3 11412T, NSP3 T1831, NSP3 T11271, NSP6 F108del, NSP6 G107del, NSP6 S106del, NSP12 P227L, NSP12 P323L, NSP14 P451S Spike A222V, Spike D614G, Spike G769V, Spike S255F, N G204R, N Q418H, N R203K, N S187L, NSP2 A306V, NSP3 51656A, NSP12 P323L, NSP14 G439R, NSP14 P412H Spike A222V, Spike D614G, Spike D118H, Spike H63del, Spike P681H, Spike S982A, Spike T716i, Spike A570D, Spike D614G, Spike D118H, Spike H63del, Spike P681H, Spike S982A, Spike T716i, Spike A570D, Spike D614G, Spike D118H, Spike H63del, NSP6 G107del, NSP6 S106del, NSP12 Spike A570D, Spike D614G, Spike D1118H, Spike H63del, Spike N501Y, Spike P681H, Spike S982A, Spike A570D, Spike D614G, Spike D1118H, Spike H63del, Spike N501Y, Spike P681H, Spike S982A, Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike N501Y, Spike P681H, Spike S982A, Spike A570D, Spike D614G, Spike D104el, N D3L, N G204R, N R14C, N R203K, N S235F, NS8 K68stop, NS8 G27stop, NS8 R52I, NS8 Y32, CNSP3 A890D, NSP3 11412T, NSP3 T183I, NSP6 F108del, NSP6 Spike A5701Y, Spike D513G, Spike D6164G, Spike T951, N M234I, N P199L, NS3 P42L, NS3 C57H, NS8 A65V, NS8 T131, NSP2 T851, NSP4 L438P, NSP6 F108del, NSP6 G107del, NSP6 S106del, NSP6 G107del, NSP6 S106d
P21-2364 P21-2378 P21-2382 P21-2105 P21-2105 P21-2137 P21-2137 P21-2143	59 20 26 97 66 67 55	Pfizer Pfizer Pfizer Pfizer Pfizer Pfizer Pfizer Pfizer Pfizer	not hospitalized not hospitalized not hospitalized not hospitalized not hospitalized hospitalized hospitalized but not for covid	M M M F F	61-70 61-70 21-30 21-30 31-40 81-90	31.03 25.32 18.13 20.16 20.61 17.78 19.58	EPI_ISL_1922853 EPI_ISL_1922863 EPI_ISL_1922867 EPI_ISL_2202770 EPI_ISL_2202770 EPI_ISL_1922859 EPI_ISL_1790005 EPI_ISL_1790010	NYULH1616 NYULH1627 NYULH1631 NYULH1631 NYULH1344 NYULH1374 NYULH1379	GR GR GR GH GH	B.1.1.7 B.1.1 B.1.1.7 B.1.526 B.1.526 B.1.526	R52I, NS8 Y32C, NSP3 A890D, NSP3 11412T, NSP3 T183I, NSP3 T1127I, NSP6 F108del, NSP6 G107del, NSP6 S106del, NSP12 P227L, NSP12 P323L, NSP14 P451S Spike A222V, Spike D614G, Spike G769V, Spike S255F, N G204R, N Q418H, N R203K, N S187L, NSP2 A30CV, NSP3 S1565A, NSP12 P323L, NSP14 P451S Spike A570D, Spike D614G, Spike G769V, Spike S255F, N G204R, N Q418H, N R203K, N S187L, NSP2 A30CV, NSP3 S1565A, NSP12 P323L, NSP14 S43P412H Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike P681H, Spike S982A, Spike T716I, Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike NS8 C61F, NS8 K68stop, NS8 Q27stop, NS8 R52L, NS8 V73C, NSP3 A890D, NS9 F102del, NSP6 G107del, NSP6 S106del, NSP12 P32TL, NS912 P323L Spike A7010, Spike D14G, Spike D1118H, Spike H69del, Spike N501Y, Spike P681H, Spike S982A, Spike A7010, Spike D523G, Spike D614G, Spike T951, N M234L, N T199L, NS3 P42L, NS3 P104L, NS5 Spike A701V, Spike D523G, Spike D614G, Spike T951, N M234L, N P199L, NS3 P42L, NS3 P104L, NS3 Spike A701V, Spike D523G, Spike D614G, Spike T85L, NSP4 L438P, NSP6 F108del, NSP6 G107del, NSP6 Spike A701V, Spike D53G, Spike D614G, Spike T85L, NSP3 L4138P, NSP6 F108del, NSP6 G107del, NSP5 Spike A701V, Spike D53G, Spike D614G, Spike E484K, Spike L5F, Spike T95L, N M234L, N P199L, NS3 Spike A701V, Spike D53G, Spike D614G, Spike E48L, Spike L5F, Spike T95L, N M234L, N P199L, NS3 Spike A701V, Spike D53G, Spike D614G
P21-2364 P21-2378 P21-2382 P21-2105 P21-2372 P21-2137 P21-2143	59 20 26 97 66 67 55	Pfizer Pfizer Pfizer Pfizer Pfizer Moderna Pfizer	not hospitalized not hospitalized not hospitalized not hospitalized not hospitalized not hospitalized but not for covid	M M M F	61-70 61-70 21-30 21-30 31-40 81-90 61-70	31.03 25.32 18.13 20.16 20.61 17.78 19.58	EPI_ISL_1922853 EPI_ISL_1922863 EPI_ISL_1922867 EPI_ISL_2202770 EPI_ISL_1922859 EPI_ISL_1790005 EPI_ISL_1790010	NYULH1616 NYULH1627 NYULH1631 NYULH1344 NYULH1344 NYULH1374 NYULH1379	GR GR GR GRY GH GH	B.1.1.7 B.1.1 B.1.1.7 B.1.526 B.1.526 B.1.526	R52I, NS8 Y73C, NSP3 A890D, NSP3 11412T, NSP3 T183I, NSP3 T1127I, NSP6 F108del, NSP6 G107del, NSP6 S106del, NSP12 P22T, NSP12 P323, NSP14 P451S Spike A222V, Spike D614G, Spike G769V, Spike S255F, N G204R, N Q418H, N R203K, N S187L, NSP2 A306V, NSP3 S1656A, NSP12 P323L, NSP14 P451S Spike A222V, Spike D614G, Spike G769V, Spike S255F, N G204R, N Q418H, N R203K, N S187L, NSP2 A306V, NSP3 S1656A, NSP12 P323L, NSP14 P412H Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike P681H, Spike S982A, Spike T716I, Spike K700b, Spike D614G, Spike D1118H, Spike H69del, Spike P681H, Spike S982A, Spike T716I, Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike N501Y, Spike P681H, Spike S982A, Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike N501Y, Spike P681H, Spike S982A, Spike A7700, Spike D614G, Spike D1118H, Spike H69del, Spike N501Y, Spike P681H, Spike S982A, Spike A701V, Spike D516G, Spike D1118H, Spike H69del, Spike N501Y, Spike P681H, Spike S982A, Spike A701V, Spike D230S, Spike D614G, Spike T951, N M234I, N P199L, NS3 P104L, NS3 Q57H, NS 8452, NSP S1504Gel, NSP2 1758, NSP3 51588L, NSP4 L438P, NSP6 F108del, NSP6 G107del, NSP6 5106del, NSP12 P323L, NSP13 Q88H Spike A701V, Spike D253G, Spike D614G, Spike E484K, Spike L5F, Spike T951, N M234I, N P199L, NS3 Spike A701V, Spike D253G, Spike D614G, Spike E484K, Spike L5F, Spike T951, N M234I, N P199L, NS4 Spike A701V, Spike D253G
P21-2364 P21-2378 P21-2382 P21-2105 P21-2105 P21-2372 P21-2137 P21-2143 P21-2143	59 20 26 97 66 67 55 54	Pfizer Pfizer Pfizer Pfizer Pfizer Pfizer Pfizer Moderna Pfizer Moderna	not hospitalized not hospitalized not hospitalized not hospitalized not hospitalized hospitalized but not for covid not hospitalized	M M M F F	61-70 61-70 21-30 21-30 31-40 81-90 61-70	31.03 25.32 18.13 20.16 20.61 17.78 19.58 20.33	EPI_ISL_1922853 EPI_ISL_1922863 EPI_ISL_1922867 EPI_ISL_1922867 EPI_ISL_1922859 EPI_ISL_1790005 EPI_ISL_1790010 EPI_ISL_1790010	NYULH1616 NYULH1627 NYULH1631 NYULH1631 NYULH1344 NYULH1622 NYULH1379 NYULH1379	GR GR GR GRY GH GH GH	B.1.1.7 B.1.1 B.1.1.7 B.1.1.7 B.1.526 B.1.526 B.1.526 B.1.526	S21, NS8 Y73C, NSP3 A890D, NSP3 11412T, NSP3 T1831, NSP3 T11271, NSP6 F108del, NSP6 G107del, NSP6 S106del, NSP12 P227L, NSP12 P323L, NSP14 P451S Spike A222V, Spike D614G, Spike G769V, Spike S255F, N G204R, N Q418H, N R203K, N S187L, NSP2 A306V, NSP3 S1656A, NSP12 P323L, NSP13 G439R, NSP14 P421C Spike A570D, Spike D614G, Spike D118H, Spike H69del, Spike P681H, Spike S982A, Spike T716i, Spike N70de, Spike D614G, Spike D1118H, Spike H69del, Spike P681H, Spike S982A, Spike T716i, Spike N70D, Spike D614G, Spike D1118H, Spike H69del, Spike P681H, Spike S982A, Spike T716i, Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike N501Y, Spike P681H, Spike S982A, Spike T716i, Spike V70del, Spike D1118H, Spike H69del, Spike N501Y, Spike P681H, Spike S982A, Spike T716i, Spike V70del, Spike D1118H, Spike H69del, Spike N501Y, Spike P681H, Spike S982A, Spike T716i, Spike V70del, Spike P118H, Spike H69del, Spike N501Y, Spike P681H, Spike S982A, Spike T710, NSP S23, NSP 372 NSP 372 NSP3 T1821, NSP3 T1833, NSP6 F108del, NSP6 6107del, NSP6 5105del, NSP1 P2221, NSP1 P233L Spike A701V, Spike D253G, Spike D614G, Spike T484K, Spike L5F, Spike T951, N M234I, N P19U, NS3 P42L, NS3 057H, NS8 T111, NSP2 T381, NSP4 L438P, NSP6 F108del, NSP6 6107del, NSP6 5106del, NSP6 6107del, NSP6 5204, NS6 5204, NS6 5204, NS6 5204, NS6 5204, NS6 5204, NS6 52044, NS6 52044, NS6 52044, NS6 52044, NS6 52044, NS6 52044, NS6 7214, NS8 7111, NSP2 T381, NSP4 L438P, NSP6 F108del, NSP6 6107del, NSP6 61
P21-2364 P21-2378 P21-2382 P21-2105 P21-2105 P21-2372 P21-2137 P21-2143 P21-2143	59 20 26 97 66 67 55 54	Pfizer Pfizer Pfizer Pfizer Pfizer Pfizer Pfizer Moderna	not hospitalized not hospitalized not hospitalized not hospitalized not hospitalized but not for covid not hospitalized	M M M F F	61-70 61-70 21-30 21-30 31-40 81-90 61-70 51-60	31.03 25.32 18.13 20.16 20.61 17.78 19.58 20.33	EPI_ISL_1922853 EPI_ISL_1922863 EPI_ISL_1922867 EPI_ISL_1922867 EPI_ISL_1922859 EPI_ISL_1790005 EPI_ISL_1790010 EPI_ISL_1790010	NYULH1616 NYULH1627 NYULH1631 NYULH1344 NYULH1344 NYULH1374 NYULH1379 NYULH1379	GR GR GR GH GH GH	B.1.1.7 B.1.1 B.1.1.7 B.1.526 B.1.526 B.1.526 B.1.429	S21, NS8 Y73C, NSP3 A890D, NSP3 11412T, NSP3 T1831, NSP3 T11271, NSP6 F108del, NSP6 G107del, NSP6 S106del, NSP12 P227L, NSP12 P232L, NSP14 P451S Spike A222V, Spike D614G, Spike G769V, Spike S255F, N G204R, N Q418H, N R203K, N S187L, NSP2 A30CV, NSP3 S1656A, NSP12 P232L, NSP14 G439A, NSP14 P12H Spike A570D, Spike D614G, Spike D118H, Spike H69del, Spike P681H, Spike S982A, Spike T716I, Spike A570D, Spike D614G, Spike D118H, Spike H69del, Spike P681H, Spike S982A, Spike T716I, Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike N58 C01F, NS8 K68stop, NS8 Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike N501Y, Spike P681H, Spike S982A, Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike N501Y, Spike P681H, Spike S982A, Spike A701V, Spike D233G, Spike D614G, Spike T915I, N 0204R, N R14C, N R203K, N S235F, NS8 K68stop, S92 X750D, N58 R521, N58 Y73C, NSP3 A800D, NS91 11412T, NSP3 T1831, NSP6 F108del, NSP6 Spike A701V, Spike D253G, Spike D614G, Spike T951, N M234I, N P199L, NS3 P42L, NS3 P104L, NS3 Spike A701V, Spike D253G, Spike D614G, Spike T851, N M234I, N P199L, NS3 P42L, NS3 P104L, NS3 Spike A701V, Spike D253G, Spike D614G, Spike T851, N M234I, N P199L, NS3 P42L, NS3 P104L, NS3 Spike A701V, Spike D253G, Spike D614G, Spike E484K, Spike L5F, Spike T951, N M234I, N P199L, NS3 Spike A701V, Spike D253G, Spike D614G, Spike E484K, Spike L5F, Spike T951, N M234I, N P199L, NS3 Spike A701V, Spike D253G, Spike
P21-2364 P21-2378 P21-2382 P21-2105 P21-2105 P21-2372 P21-2137 P21-2143 P21-2243	59 20 26 97 66 67 55 54	Pfizer Pfizer Pfizer Pfizer Pfizer Moderna Pfizer Moderna	not hospitalized not hospitalized not hospitalized not hospitalized not hospitalized not hospitalized hospitalized but not for covid not hospitalized	M M M F F	61-70 61-70 21-30 21-30 31-40 81-90 61-70 51-60	31.03 25.32 18.13 20.16 20.61 17.78 19.58 20.33	EPI_ISL_1922853 EPI_ISL_1922863 EPI_ISL_1922867 EPI_ISL_1922867 EPI_ISL_1922859 EPI_ISL_1790005 EPI_ISL_1790010 EPI_ISL_1790010	NYULH1616 NYULH1627 NYULH1631 NYULH1344 NYULH1374 NYULH1379 NYULH1379	GR GR GR GRY GH GH GH	B.1.1.7 B.1.1 B.1.1.7 B.1.526 B.1.526 B.1.526 B.1.526 B.1.526	R52I, NS8 Y73C, NSP3 A890D, NSP3 11412T, NSP3 T183I, NSP3 T1127I, NSP6 F108del, NSP6 G107del, NSP6 S106del, NSP12 P22T, NSP12 P323L, NSP14 P451S Spike A222V, Spike D614G, Spike G769V, Spike S255F, N G204R, N Q418H, N R203K, N S187L, NSP2 A306V, NSP3 S1656A, NSP12 P323L, NSP13 G439R, NSP14 P421H Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike P681H, Spike S982A, Spike T716I, Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike P681H, Spike S982A, Spike T716I, Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike NS61V, Spike S982A, Spike T716I, Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike NS61V, Spike P681H, Spike S982A, Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike NS01V, Spike P681H, Spike S982A, Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike NS01V, Spike P681H, Spike S982A, Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike NS01V, Spike P681H, Spike S982A, Spike A701V, Spike D253G, Spike D614G, Spike T951, N M234I, N P199L, NS3 P6 F108del, NSP6 Spike A701V, Spike D253G, Spike D614G, Spike T951, N M234I, N P199L, NS3 P104L, NS3 Spike A701V, Spike D253G, Spike D614G, Spike E484K, Spike L5F, Spike T951, N M234I, N P199L, NS3 Spike A701V, Spike D253G, Spike D614G, Spike E484K, Spike L5F, Spike T951, N M234I, N P199L, NS3 Spike A701V, Spike D253G, Spike D614G, Spike E484K, Spike L5F, Spike T951, N M234I, N P199L, NS3 Spike A701V, Spike D323G, Spike D61
P21-2364 P21-2378 P21-2382 P21-2105 P21-2105 P21-2372 P21-2137 P21-2143 P21-2371	59 20 26 97 66 67 55 54	Pfizer Pfizer Pfizer Pfizer Pfizer Moderna Moderna	not hospitalized not hospitalized not hospitalized not hospitalized hospitalized hospitalized hospitalized hospitalized hospitalized Hospitalized	M M M F F	61-70 21-30 21-30 31-40 81-90 61-70 51-60	31.03 25.32 18.13 20.16 20.61 17.78 19.58 20.33	EPI_ISL_1922853 EPI_ISL_1922863 EPI_ISL_1922867 EPI_ISL_1922867 EPI_ISL_1922859 EPI_ISL_1790005 EPI_ISL_1790010 EPI_ISL_1790010	NYULH1616 NYULH1627 NYULH1631 NYULH1344 NYULH1344 NYULH1622 NYULH1379 NYULH1379	GR GR GR GRY GH GH GH	B.1.1.7 B.1.1 B.1.1.7 B.1.526 B.1.526 B.1.526 B.1.429	S21, NS8 Y73C, NSP3 A890D, NSP3 11412T, NSP3 T1831, NSP3 T11271, NSP6 F108del, NSP6 G107del, NSP6 S106del, NSP12 P227L, NSP12 P323L, NSP14 P451S Spike A222V, Spike D614G, Spike G769V, Spike S255F, N G204R, N Q418H, N R203K, N S187L, NSP2 A306V, NSP3 S1656A, NSP12 P323L, NSP14 P451S Spike A222V, Spike D614G, Spike G769V, Spike S255F, N G204R, N Q418H, N R203K, N S187L, NSP2 A306V, NSP3 S1656A, NSP12 P323L, NSP14 G439R, NSP14 P412H Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike P681H, Spike S982A, Spike T716i, Spike X70D, Spike D614G, Spike D1118H, Spike H69del, Spike N501Y, Spike P681H, Spike S982A, Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike N501Y, Spike P681H, Spike S982A, Spike A570D, Spike D614G, Spike T144del, N D3L, N G204K, N R14C, N R203K, N S235F, NS8 K68stop, S027stop, NS8 R521, NS8 Y73C, NSP3 A890D, NSP3 1142T, NSP3 T183I, NSP6 F108del, NSP6 G107del, NSP6 F198L, NSP5 5105del, NSP1 2222L, NSP1 2723L, Spike A701Y, Spike D233G, Spike D614G, Spike T951, N M234I, N P199L, NS3 P104L, NS3 Q57H, NS8 A51L, NSP1 232L, NSP1 308H Spike A701Y, Spike D233G, Spike D614G, Spike E484K, Spike L5F, Spike T951, N M234I, N P199L, NS3 Spike A701Y, Spike D233G, Spike D614G, Spike E484K, Spike L5F, Spike T951, N M234I, N P199L, NS3 Spike A701Y, Spike D233G, Spike D614G, Spike E484K, Spike L5F, Spike T951, N M234I, N P199L, NS3 Spike A701Y, Spike D253G, Spike D614G, Spike E4
P21-2364 P21-2378 P21-2382 P21-2105 P21-2105 P21-2372 P21-2137 P21-2143 P21-2371 P21-2371	59 20 26 97 66 67 55 54 27	Pfizer Pfizer Pfizer Pfizer Pfizer Pfizer Moderna Pfizer Pfizer Pfizer	not hospitalized not hospitalized not hospitalized not hospitalized hospitalized hospitalized but not for covid not hospitalized Hospitalized Hospitalized	M M M F F	61-70 61-70 21-30 21-30 31-40 81-90 61-70 51-60	31.03 25.32 18.13 20.16 20.61 17.78 19.58 20.33 30.82	EPI_ISL_1922853 EPI_ISL_1922863 EPI_ISL_1922867 EPI_ISL_2202770 EPI_ISL_1922859 EPI_ISL_1790005 EPI_ISL_1790010 EPI_ISL_1922858 EPI_ISL_1922858	NYULH1616 NYULH1627 NYULH1631 NYULH1631 NYULH1344 NYULH1622 NYULH1379 NYULH1379 NYULH1815	GR GR GR GH GH GH GH GH	B.1.1.7 B.1.1 B.1.1.7 B.1.1.7 B.1.526 B.1.526 B.1.526 B.1.429 B.1.1.7	R52I, NS8 Y73C, NSP3 A890D, NSP3 11412T, NSP3 T1831, NSP3 T1127I, NSP6 F108del, NSP6 G107del, NSP6 S106del, NSP12 P227L, NSP12 P323L, NSP14 P451S Spike A222V, Spike D614G, Spike G769V, Spike S255F, N G204R, N Q418H, N R203K, N S187L, NSP2 A306V, NSP3 S1656A, NSP12 P323L, NSP14 G439R, MSP14 P412H Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike P681H, Spike S982A, Spike T716i, Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike P681H, Spike S982A, Spike T716i, Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike P681H, Spike S982A, Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike N501Y, Spike P681H, Spike S982A, Spike A570D, Spike D614G, Spike V144del, N D3L, N G204R, N R14C, N R203K, N S235F, NS8 C65106del, NSP12 P227L, NSP12 P323L Spike A570D, Spike D614G, Spike Y144del, N D3L, N G204R, N R14C, N R203K, N S235F, NS8 K68stop, NS8 Q27stop, NS8 R52J, NS9 X73C, NSP3 A890D, NSP3 11412T, NSP3 T183I, NSP6 F108del, NSP6 G107del, NSP6 G107del, NSP6 G107del, NSP6 S106del, NSP12 P227L, NSP12 P323L Spike A5701V, Spike D253G, Spike D614G, Spike T951, N M234I, N P19L, NS3 Q57H, NS8 A65V, NS8 T111, NSP3 T183I, NSP4 L438P, NSP6 F108del, NSP6 G107del, NSP6 G10
P21-2364 P21-2378 P21-2382 P21-2105 P21-2105 P21-2372 P21-2137 P21-2143 P21-2764	59 20 26 97 66 67 55 54 27	Pfizer Pfizer Pfizer Pfizer Pfizer Pfizer Moderna Pfizer Pfizer	not hospitalized not hospitalized not hospitalized not hospitalized not hospitalized not hospitalized but not for covid not hospitalized but not for covid not hospitalized	M M M F F F	61-70 21-30 21-30 31-40 81-90 61-70 51-60 21-30	31.03 25.32 18.13 20.16 20.61 17.78 19.58 20.33 30.82	EPI_ISL_1922853 EPI_ISL_1922863 EPI_ISL_1922867 EPI_ISL_1922867 EPI_ISL_1922859 EPI_ISL_1790005 EPI_ISL_1790010 EPI_ISL_1790010 EPI_ISL_1922858 EPI_ISL_1922858	NYULH1616 NYULH1627 NYULH1631 NYULH1344 NYULH1374 NYULH1374 NYULH1379 NYULH1379	GR GR GR GH GH GH GH GH	B.1.1.7 B.1.1 B.1.1.7 B.1.526 B.1.526 B.1.526 B.1.526 B.1.429 B.1.1.7	F52I, NS8 Y73C, NSP3 A890D, NSP3 11412T, NSP3 T1831, NSP3 T11271, NSP6 F108del, NSP6 G107del, NSP6 S106del, NSP12 P227L, NSP12 P323L, NSP14 P451S Spike A222V, Spike D614G, Spike G769V, Spike S255F, N G204R, N Q418H, N R203K, N S187L, NSP2 A306V, NSP3 S1656A, NSP12 P323L, NSP13 G439R, NSP14 P421H Spike A570D, Spike D614G, Spike D118H, Spike H69del, Spike P681H, Spike S982A, Spike T716I, Spike X700L, Spike D614G, Spike D118H, Spike H69del, Spike P581H, Spike S982A, Spike T716I, Spike X700D, Spike D614G, Spike D1118H, Spike H69del, Spike N501Y, Spike S982A, Spike X700D, Spike D614G, Spike D1118H, Spike H69del, Spike N501Y, Spike P681H, Spike S982A, Spike X700D, Spike D614G, Spike D1118H, Spike H69del, Spike N501Y, Spike P681H, Spike S982A, Spike X701V, Spike D213G, Spike D1118H, Spike H69del, Spike N501Y, Spike P681H, Spike S982A, Spike X701V, Spike D233G, Spike D614G, Spike T951, N M2341, N P1991, NS3 P421, NS3 P104L, NS3 Spike X701Y, Spike D253G, Spike D614G, Spike T951, N M2341, N P1991, NS3 P421, NS3 P104L, NS3 Spike X701Y, Spike D253G, Spike D614G, Spike T851, NM2341, N P1991, NS3 P421, NS3 P104L, NS3 Spike X701Y, Spike D253G, Spike D614G, Spike T851, NM2341, N P1991, NS3 P421, NS3 P104L, NS3 Spike X701Y, Spike D253G, Spike D614G, Spike T851, NSP1 4138P, NSP6 F108del, NSP6 G107del, NSP6 Spike X701Y, Spike D253G, Spike D614G, Spike T851, NSP4 L338P, NSP6 F108del, NSP6 G107del, NSP6 Spike X701Y, Spike D253G, Spike D614G, Sp
P21-2364 P21-2378 P21-2382 P21-2105 P21-2105 P21-2372 P21-2137 P21-2143 P21-2271 P21-2764 P21-2764	59 20 26 97 66 67 55 54 27 61	Pfizer Pfizer Pfizer Pfizer Pfizer Pfizer Moderna Pfizer Pfizer Pfizer Pfizer Pfizer Pfizer Pfizer	not hospitalized not hospitalized not hospitalized not hospitalized not hospitalized hospitalized but not for covid hospitalized hospitalized for COVID not hospitalized	M M M F F	61-70 61-70 21-30 21-30 31-40 81-90 61-70 51-60 21-30	31.03 25.32 18.13 20.16 20.61 17.78 19.58 20.33 30.82 24.47	EPI_ISL_1922853 EPI_ISL_1922863 EPI_ISL_1922867 EPI_ISL_1922867 EPI_ISL_1922859 EPI_ISL_1790010 EPI_ISL_1790010 EPI_ISL_1790010 EPI_ISL_1922858 EPI_ISL_178994	NYULH1616 NYULH1627 NYULH1631 NYULH1344 NYULH1344 NYULH1622 NYULH1379 NYULH1379 NYULH1815	GR GR GR GH GH GH GH GH	B.1.1.7 B.1.1 B.1.1.7 B.1.526 B.1.526 B.1.526 B.1.526 B.1.429 B.1.1.7 B.1.526	S21, NS8 Y73C, NSP3 A890D, NSP3 11412T, NSP3 T1831, NSP3 T11271, NSP6 F108del, NSP6 G107del, NSP6 S106del, NSP12 P22T, NSP12 P323, NSP14 P4515 Spike A222V, Spike D614G, Spike G769V, Spike S255F, N G204R, N Q418H, N R203K, N S187L, NSP2 A306V, NSP3 S1656A, NSP12 P323L, NSP14 G439A, NSP14 P4216 Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike P681H, Spike S982A, Spike T716I, Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike P681H, Spike S982A, Spike T716I, Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike N507, Spike C506del, NSP12 P227L, NSP12 P323L, NSP13 G439R, NSP14 NSP6 G107del, NSP6 S106del, NSP5 Spike A7010, Spike D614G, Spike T144del, N D3L, N G204R, N R14C, N R203K, N S235F, NS8 K68stop, Sqike A7010, Spike D614G, Spike T118H, Spike H69del, Spike N5017, Spike P681H, Spike S982A, Spike A7010, Spike D513G, Spike D614G, Spike T951, N M234I, N P199L, NS9 F108del, NSP6 Spike A701V, Spike D253G, Spike D614G, Spike T951, N M234I, N P199L, NS3 P104L, NS3 Q57H, NS 8111, NSP1 238L, NSP1 283, NSP4 L438P, NSP6 F108del, NSP6 G107del, Spike A701V, Spike D253G, Spike D614G, Spike E484K, Spike L5F, Spike T951, N M234I, N P199L, NS3 Spike A701V, Spike D253G, Spike D614G, Spike E484K, Spike L5F, Spike T951, N M234I, N P199L, NS3 Spike A701V, Spike D253G, Spike D614G, Spike E484K, Spike L5F, Spike T951, N M234I, N P199L, NS3 Spike A701V, Spike D253G, Spike D614G, Spike K5120K, NSP4 L438P, NSP6 F108del, NSP

					51-60						Spike A701V, Spike D253G, Spike D614G, Spike E484K, Spike T95I, N M234I, N P199L, NS3 P42L, NS3
			not								Q57H, NS8 T11I, NSP2 T85I, NSP4 L438P, NSP6 F108del, NSP6 G107del, NSP6 S106del, NSP12 P323L,
P21-2375	105	Pfizer	hospitalized	М		30.32	EPI_ISL_1922861	NYULH1624	GH	B.1.526	NSP13 Q88H
			hospitalized		71-80						Spike A1078S, Spike D614G, Spike P681H, Spike T716I, M I82T, N G96C, N K127R, N L224F, N T205I,
			but not for								NS3 Q57H, NSP2 S122F, NSP2 T85I, NSP3 A333S, NSP4 T492I, NSP6 T181I, NSP12 A97V, NSP12
P21-2381	64	Moderna	covid	м		22.14	EPI_ISL_1922866	NYULH1630	GH	B.1.575	P323L, NSP13 P47S
					51-60						Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike N501Y, Spike P681H, Spike S982A,
											Spike T716I, Spike V70del, Spike Y144del, E S68F, N D3L, N G204R, N R203K, N S235F, NS3 D210Y,
			Hospitalized								NS8 K68stop, NS8 Q27stop, NS8 R52I, NS8 Y73C, NSP3 A890D, NSP3 I1412T, NSP3 M1441I, NSP3
P21-2386	31	Pfizer	for COVID	F		21.52	EPI_ISL_1922871	NYULH1635	GRY	B.1.1.7	T183I, NSP6 F108del, NSP6 G107del, NSP6 S106del, NSP12 P227L, NSP12 P323L, NSP13 A509V
					31-40						
			not								Spike D614G, Spike H655Y, N T205I, NS3 S253P, NS3 V256F, NS8 E92K, NSP6 F108del, NSP6
P21-2594	102	Pfizer	hospitalized	F		18.22	EPI_ISL_2161782	NYULH1812	G	B.1	G107del, NSP6 S106del, NSP13 E341D
					31-40						Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike N501Y, Spike P681H, Spike S982A,
											Spike T716I, Spike V70del, Spike V327I, Spike Y144del, N D3L, N G204R, N R203K, N S235F, NS8
			not								K68stop, NS8 Q27stop, NS8 R52I, NS8 Y73C, NSP3 A890D, NSP3 I1412T, NSP3 T183I, NSP6 F108del,
P21-2573	100	Pfizer	hospitalized	F		19.32	EPI_ISL_2161767	NYULH1792	GRY	B.1.1.7	NSP6 G107del, NSP6 S106del, NSP12 P227L, NSP12 P323L, NSP14 P451S
					21-30						Spike A701V, Spike D253G, Spike D614G, Spike T95I, N M234I, N P199L, NS3 P42L, NS3 P262S, NS3
			not						1	1	Q57H, NS8 T11I, NSP2 T85I, NSP3 P1469S, NSP3 S1396T, NSP4 L438P, NSP6 F108del, NSP6 G107del,
P21-2592	99	Pfizer	hospitalized	F		25.37	EPI_ISL_2161781	NYULH1811	GH	B.1.526	NSP6 S106del, NSP12 P323L, NSP13 Q88H

Spike pos	5	69	70	80	144	157	222	417	477	484	501	570	655	681	716	859	950	982	1027	1118	1191
SARS-CoV- 2/Wuhan-Hu-1	L	Н	V	D	Y	F	А	К	S	E	Ν	А	Н	Р	Т	Т	D	S	Т	D	К
spike mutation	L5X	H69X	V70X	D80X	Y144X	F157X	A222X	K417X	S477X	E484X	N501X	A570X	H655X	P681X	T716X	T859X	D950X	S982X	T1027X	D1118X	K1191X
important sites		d	el		del				RBD (aa S	331 - 524)				VOCs (UK & India)							
Unvacc-ctr WT (%)	62.42	69.47	70.82	89.63	59.52	89.36	99.32	98.5	89.31	76.06	69.51	70.99	98.9	62.06	68.49	90.1	90	70.91	98.9	70.78	98.11
Unvacc-ctr mut (%)	37.58	30.53	29.18	10.37	40.48	10.64	0.68	1.5	10.69	23.94	30.49	29.01	1.1	37.94	31.51	9.9	10	29.09	1.1	29.22	1.89
Vacc WT (%)	61.76	62.12	62.12	89.23	46.55	87.93	96.77	96.43	87.5	70	62.5	59.7	96.97	54.55	58.21	89.23	88.24	62.12	97.01	61.9	95.16
Vacc mut (%)	38.24	37.88	37.88	10.77	53.45	12.07	3.23	3.57	12.5	30	37.5	40.3	3.03	45.45	41.79	10.77	11.76	37.88	2.99	38.1	4.84
Difference: Vacc (%) minus Unvacc- ctrl (%) (enrichment)	0.66	7.35	8.7	0.4	12.97	1.43	2.55	2.07	1.81	6.06	7.01	11.29	1.93	7.51	10.28	0.87	1.76	8.79	1.89	8.88	2.95
p (Fisher)	1	0.22	0.17	0.84	0.06	0.67	0.09	0.23	0.64	0.35	0.38	0.05	0.19	0.24	0.08	0.83	0.63	0.13	0.19	0.16	0.13
q (multiplicity correction, BH)	1	0.39	0.39	0.88	0.39	0.78	0.39	0.39	0.78	0.53	0.54	0.39	0.39	0.39	0.39	0.88	0.78	0.39	0.39	0.39	0.39

Supplementary Table 4: Spike mutation statistics at 21 sites with enriched mutation rates in vaccine breakthrough infections in New York.

Supplementary Figures.



Supplementary Figure 1. Spike mutation patterns in vaccine breakthrough sequences.
A) Highlighter plot showing spike amino acid mutations of 67 vaccine breakthrough SARS-CoV-2 sequences compared to the Wuhan-Hu-1 reference sequence as master (top line). Mutations are shown as ticks, color-coded according to the legend at the bottom. Key mutations are indicated by triangles and labeled. Study sequences are sorted according to the Neighbor-joining tree to the right (B). The scale bar at the bottom indicates the branch length of two substitutions. B.1.1.7 and B.1.526 sequences are highlighted in blue and purple, respectively.

Supplementary Methods

cDNA synthesis, library preparation and sequencing

Total RNA (11 μ l) was converted to first strand cDNA by random priming using the Superscript IV first-strand synthesis system (Invitrogen, ref# 180901050). Random priming was performed as follows: 65°C for 5 mins, cooled on ice followed by addition of mix to run cDNA first strand synthesis 23°C 10mins, 50°C for 1 hour, 80°C for 10 mins, and 4°C hold. Libraries were prepared using Swift Normalase Amplicon Panel (SNAP) SARS-CoV-2 and Sar-Cov-2 additional Genome Coverage (Cat# SN-5X296 core kit, 96rxn), using 10 µl of first strand cDNA, following the manufacturer's instruction: https://swiftbiosci.com/wp-content/uploads/2021/06/PRT-028-Swift-Normalase-Amplicon-Panels-SNAP-SARS-CoV-2-Panels-Rev-9.pdf). First step incorporated tiled primer pairs which target and enrich for the entire 29.9kb covid-19 viral genome (NCBI Reference Sequence NC 045512.2) during multiplex PCR. Multiplex PCR was run as follows: 98°C 30 secs, 4 repeating cycles of 98°C/ 10secs, 61°C/5mins, 65°C/1min. 24 repeating cycles of 98°C/10secs, 64°C/1min followed by 1 cycle of 65°C for 1 min and held at 4 °C. The multiplexed samples were cleaned with 1x volume room temperature Ampure XP beads (Beckman Coulter, #A63882) for 5 mins, washed with 80% ethanol twice, and beads were resuspended in 17.4ul of TE buffer (part of swift kit). Indexing reagent mix was added to the resuspended beads. One unique SNAP UD dual indexing primer pair was added to each sample. Indexing PCR was run at 37°C/20mins, 98°C/30secs, 9 repeating cycles of 98°C/10secs, 60°C/30secs, 66°C/1min. After indexing PCR was completed, samples were cleaned with 32.5ul of PEG NaCl solution (provided in swift kit, 5min bind time, 80% ethanol wash x2) and eluted in 20ul of post PCR TE buffer. Final libraries were run on Agilent Tapestation 2200 with high sensitivity DNA Screentape to verify amplicon size of about 450 bp. Samples were pooled according to the enzymatic normalase step. The loading concentration for the normalized pool was verified on QPCRusing the Kapa library quantification complete kit (Kapa-Roche, #KK4824) run on the Bio-Rad CFX384 Real-time system. Normalized pools were run on the Illumina NovaSeq 6000 system with the SP 300 cycle flow cell. Run metrics were paired end 150 cycles with dual indexing reads. Typically, 2 pools representing 2 full 96 well plates (192 samples) were sequenced on each SP300 NovaSeq flow cell.

Sequenced read processing

Binary base call files outputted by the Illumina NovaSeq 6000 sequencing instrument (RTA Version 3.4.4) were converted to FASTQ format and demultiplexed according to the unique dual-index adapter sequences of each sample using the Illumina bcl2fastq2 Conversion Software v2.20. Adapters and low quality bases were trimmed using Trimmomatic v0.36 (Bolger et al. 2014) with the settings 'ILLUMINACLIP:trimmomatic.fa:2:30:10:1:true TRAILING:5 SLIDINGWINDOW:4:15 MINLEN:35'. The BWA-MEM algorithm of the alignment program, BWA v0.7.17 (Li and Durbin 2009), was utilized for mapping reads of each sample to the SARS-CoV-2 reference genome (NC_045512.2, wuhCor1) with the '-M' flag for marking shorter split hits as secondary and the parameter '-U' set to a 17 alignment score penalty for an unpaired read pair. Name-sorted mapped reads in SAM alignment format were soft-clipped to remove primer sequences specific to the short overlapping (tiled) amplicon design of the Swift Normalase

Amplicon SARS-CoV-2 Panel using Primerclip v0.3.8 (Swift Biosciences: https://github.com/swiftbiosciences/primerclip), and the Picard v2.18.20

"AddOrReplaceReadGroups" tool (Broad Institute: http://broadinstitute.github.io/picard/) was used in converting the primer-trimmed SAM files to coordinate-sorted and indexed BAM format with read-groups added for downstream analysis. The variant caller, BCFtools v1.9 (Li et al. 2009), was utilized to detect genetic mutations of the collected viral samples from BAM input: bcftools mpileup -r NC_045512.2 --count-orphans --no-BAQ --max-depth 50000 --max-idepth 500000 --annotate

FORMAT/AD,FORMAT/ADF,FORMAT/ADR,FORMAT/DP,FORMAT/SP,INFO/AD,INFO/ADF,INFO/A DR --output-type v |

bcftools call --ploidy 1 --keep-alts --multiallelic-caller --output-type v |

bcftools norm --multiallelics -any --output-type v |

bcftools filter -i "(DP4[0]+DP4[1])<(DP4[2]+DP4[3]) && ((DP4[2]+DP4[3])>0) &

FORMAT/AD[0:1]>20" --output-type v |

bcftools filter -e "IMF<0.5" --output-type v

To generate viral sequences, the output in VCF format was applied to the reference sequence using `bcftools consensus` while the BEDTools v2.30.0 utilities (Quinlan and Hall 2010), "genomecov" (with the '-bga' option to report depth at each base including zero coverage sites), "merge" (for creating a BED file of low depth sites with <1000x coverage to be masked), and "maskfasta" in conjunction with the multiple sequence alignment program, MAFFT v4.471 (Katoh et al. 2002) in '--auto' mode, were used in the production of final consensus sequences with all bases below 1000x coverage masked and both non-targeted ends of the sequences trimmed. Sequences with fewer than 23,000 bp with at least 4000x coverage were discarded from further analysis for having not yielded a near-complete SARS-CoV-2 genome, resulting in 1,254 final sequences suitable for downstream analysis (Supplemental Table). Each assembled SARS-CoV-2 genome sequence was assigned the most likely phylogenetic lineage according to Phylogenetic Assignment of Named Global Outbreak Lineages (PANGO) nomenclature (Rambaut et al. 2020) using the PANGO lineage tool (version: 2021-06-05).

References

1. Worldometer. COVID-19 Coronavirus Pandemic. Accessed June 15th, 2021, <u>https://www.worldometers.info/coronavirus/</u>

2. Wu F, et al. A new coronavirus associated with human respiratory disease in China. *Nature*. Mar 2020;579(7798):265-269. doi:10.1038/s41586-020-2008-3

3. Baden LR, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med*. Feb 4 2021;384(5):403-416. doi:10.1056/NEJMoa2035389

4. Polack FP, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med*. Dec 31 2020;383(27):2603-2615. doi:10.1056/NEJMoa2034577

5. Sadoff J, et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. *N Engl J Med*. Apr 21 2021;doi:10.1056/NEJMoa2101544

6. Dagan N, et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. *N Engl J Med*. Feb 24 2021;doi:10.1056/NEJMoa2101765

7. Daniel W, et al. Early Evidence of the Effect of SARS-CoV-2 Vaccine at One Medical Center. *New England Journal of Medicine*. 2021;doi:10.1056/NEJMc2102153

8. Thompson MG, et al. Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S. Locations, December 2020-March 2021. *MMWR Morb Mortal Wkly Rep*. Apr 2 2021;70(13):495-500. doi:10.15585/mmwr.mm7013e3

9. Rossman H, et al. COVID-19 dynamics after a national immunization program in Israel. *Nat Med*. Apr 19 2021;doi:10.1038/s41591-021-01337-2

10. Haas EJ, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. *Lancet*. May 15 2021;397(10287):1819-1829. doi:10.1016/S0140-6736(21)00947-8

11. Chodick G, et al. The effectiveness of the TWO-DOSE BNT162b2 vaccine: analysis of realworld data. *Clin Infect Dis*. May 17 2021;doi:10.1093/cid/ciab438

12. Pilishvili T, et al. Interim Estimates of Vaccine Effectiveness of Pfizer-BioNTech and Moderna COVID-19 Vaccines Among Health Care Personnel - 33 U.S. Sites, January-March 2021. *MMWR Morb Mortal Wkly Rep*. May 21 2021;70(20):753-758. doi:10.15585/mmwr.mm7020e2

13. Vanker A, et al. Adverse Outcomes Associated with SARS-CoV-2 variant B.1.351 Infection in Vaccinated Residents of a Long Term Care Home, Ontario, Canada. *Clin Infect Dis*. Jun 6 2021;doi:10.1093/cid/ciab523

14. Thompson CN, et al. Rapid Emergence and Epidemiologic Characteristics of the SARS-CoV-2 B.1.526 Variant - New York City, New York, January 1-April 5, 2021. *MMWR Morb Mortal Wkly Rep.* May 14 2021;70(19):712-716. doi:10.15585/mmwr.mm7019e1

15. Teran RA, et al. Postvaccination SARS-CoV-2 Infections Among Skilled Nursing Facility Residents and Staff Members - Chicago, Illinois, December 2020-March 2021. *MMWR Morb Mortal Wkly Rep*. Apr 30 2021;70(17):632-638. doi:10.15585/mmwr.mm7017e1

16. Pollett SD, et al. The SARS-CoV-2 mRNA vaccine breakthrough infection phenotype includes significant symptoms, live virus shedding, and viral genetic diversity. *Clin Infect Dis*. Jun 12 2021;doi:10.1093/cid/ciab543

17. Kustin T, et al. Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals. *Nat Med*. Jun 14 2021;doi:10.1038/s41591-021-01413-7

18. Jacobson KB, et al. Post-vaccination SARS-CoV-2 infections and incidence of the B.1.427/B.1.429 variant among healthcare personnel at a northern California academic medical center. *medRxiv*. Apr 24 2021;doi:10.1101/2021.04.14.21255431

19. Hacisuleyman E, et al. Vaccine Breakthrough Infections with SARS-CoV-2 Variants. *N Engl J Med*. Jun 10 2021;384(23):2212-2218. doi:10.1056/NEJMoa2105000

20. Cdc Covid- Vaccine Breakthrough Case Investigations Team. COVID-19 Vaccine Breakthrough Infections Reported to CDC - United States, January 1-April 30, 2021. *MMWR Morb Mortal Wkly Rep*. May 28 2021;70(21):792-793. doi:10.15585/mmwr.mm7021e3

21. Cavanaugh AM, et al. COVID-19 Outbreak Associated with a SARS-CoV-2 R.1 Lineage Variant in a Skilled Nursing Facility After Vaccination Program - Kentucky, March 2021. *MMWR Morb Mortal Wkly Rep*. Apr 30 2021;70(17):639-643. doi:10.15585/mmwr.mm7017e2

22. Duerr R, et al. SARS-CoV-2 Portrayed Against HIV: Contrary Viral Strategies in Similar Disguise. *Preprints*. 2021;2021040193. doi:10.20944/preprints202104.0193.v1

23. Wang R, et al. Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species. *Immunity*. 2021/06/08/ 2021;doi:<u>https://doi.org/10.1016/j.immuni.2021.06.003</u>

24. West AP, et al. SARS-CoV-2 lineage B.1.526 emerging in the New York region detected by software utility created to query the spike mutational landscape. *bioRxiv*. 2021:2021.02.14.431043. doi:10.1101/2021.02.14.431043

25. Annavajhala MK, et al. A Novel SARS-CoV-2 Variant of Concern, B.1.526, Identified in New York. *medRxiv*. 2021:2021.02.23.21252259. doi:10.1101/2021.02.23.21252259

26. SWIFT Protocol. Swift Normalase[™] Amplicon Panels (SNAP). <u>https://swiftbiosci.com/wp-content/uploads/2021/06/PRT-028-Swift-Normalase-Amplicon-Panels-SNAP-SARS-CoV-2-Panels-Rev-9.pdf</u>

27. Bolger AM, et al. Trimmomatic: a flexible trimmer for Illumina sequence data. *Bioinformatics*. Aug 1 2014;30(15):2114-20. doi:10.1093/bioinformatics/btu170

28. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics*. Jul 15 2009;25(14):1754-60. doi:10.1093/bioinformatics/btp324

29. SWIFT Biosciences. Primerclip. <u>https://github.com/swiftbiosciences/primerclip</u>

30. Li H, et al. The Sequence Alignment/Map format and SAMtools. *Bioinformatics*. Aug 15 2009;25(16):2078-9. doi:10.1093/bioinformatics/btp352

31. Rambaut A, et al. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. *Nature Microbiology*. 2020/11/01 2020;5(11):1403-1407. doi:10.1038/s41564-020-0770-5

32. CBRC. MAFFT version 7. Accessed June 7th, 2021,

https://mafft.cbrc.jp/alignment/software/closelyrelatedviralgenomes.html

33. Miller MA, et al. Creating the CIPRES Science Gateway for Inference of Large Phylogenetic Trees. 2010:1-8.

Letunic I, Bork P. Interactive Tree Of Life (iTOL) v4: recent updates and new
 developments. *Nucleic acids research*. Jul 2 2019;47(W1):W256-W259. doi:10.1093/nar/gkz239
 B. Core Team, B: A language and environment for statistical computing. http://www.Ra

35. R Core Team. R: A language and environment for statistical computing. <u>http://www.R-project.org/</u>

36. RStudio Team. RStudio: Integrated Development for R. . RStudio, Inc., Boston, MA <u>http://www.rstudio.com/</u>

37. Los Alamos National Laboratory tools. Highlighter tool. <u>http://www.hiv.lanl.gov/</u>

38. D'Agostino RB, Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. *Stat Med*. Oct 15 1998;17(19):2265-81. doi:10.1002/(sici)1097-0258(19981015)17:19<2265::aid-sim918>3.0.co;2-b

39. Ho DE, et al. MatchIt: Nonparametric Preprocessing for Parametric Causal Inference. Journal of Statistical Software. 2011;42(8):1--28.

40. Kidd M, et al. S-variant SARS-CoV-2 lineage B1.1.7 is associated with significantly higher viral loads in samples tested by ThermoFisher TaqPath RT-qPCR. *J Infect Dis*. Feb 13 2021;doi:10.1093/infdis/jiab082

41. Frampton D, et al. Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study. *Lancet Infect Dis*. Apr 12 2021;doi:10.1016/S1473-3099(21)00170-5

42. McCormick KD, et al. The emerging plasticity of SARS-CoV-2. *Science*. Mar 26 2021;371(6536):1306-1308. doi:10.1126/science.abg4493

43. Greaney AJ, et al. Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition. *Cell Host Microbe*. Jan 13 2021;29(1):44-57 e9. doi:10.1016/j.chom.2020.11.007

44. McCarthy KR, et al. Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape. *Science*. Feb 3 2021;doi:10.1126/science.abf6950

45. Washington NL, et al. Emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United States. *Cell*. May 13 2021;184(10):2587-2594 e7. doi:10.1016/j.cell.2021.03.052

46. Davies NG, et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. *Science*. 2021:eabg3055. doi:10.1126/science.abg3055

47. Volz E, et al. Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. *Nature*. Mar 25 2021;doi:10.1038/s41586-021-03470-x

48. Kissler S, et al. Densely sampled viral trajectories suggest longer duration of acute infection with B.1.1.7 variant relative to non-B.1.1.7 SARS-CoV-2. *Preprint*. 2021;

49. Ratcliff J, et al. Virological and serological characterization of critically ill patients with COVID-19 in the UK: Interactions of viral load, antibody status and B.1.1.7 variant infection. *J Infect Dis.* May 24 2021;doi:10.1093/infdis/jiab283

50. Davies NG, et al. Increased hazard of death in community-tested cases of SARS-CoV-2 Variant of Concern 202012/01. *medRxiv*. 2021:2021.02.01.21250959. doi:10.1101/2021.02.01.21250959

51. Iacobucci G. Covid-19: New UK variant may be linked to increased death rate, early data indicate. *BMJ*. Jan 26 2021;372:n230. doi:10.1136/bmj.n230

52. Challen R, et al. Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. *BMJ*. 2021;372:n579. doi:10.1136/bmj.n579

53. Grint DJ, et al. Case fatality risk of the SARS-CoV-2 variant of concern B.1.1.7 in England, 16 November to 5 February. *Eurosurveillance*. 2021;26(11):2100256.

doi:doi:https://doi.org/10.2807/1560-7917.ES.2021.26.11.2100256

54. Collier DA, et al. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. *Nature*. 2021/03/11 2021;doi:10.1038/s41586-021-03412-7

55. Starr TN, et al. Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding. *Cell*. Sep 3 2020;182(5):1295-1310 e20. doi:10.1016/j.cell.2020.08.012

56. Gu H, et al. Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy. *Science*. 2020;369(6511):1603-1607. doi:10.1126/science.abc4730

57. Meng B, et al. Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the variant of concern lineage B.1.1.7. *Cell reports*. doi:10.1016/j.celrep.2021.109292

58. Shen X, et al. SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines. *Cell Host & Microbe*. 2021;doi:10.1016/j.chom.2021.03.002

59. Emary KRW, et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. *The Lancet*. doi:10.1016/S0140-6736(21)00628-0

60. Munitz A, et al. BNT162b2 vaccination effectively prevents the rapid rise of SARS-CoV-2 variant B.1.1.7 in high-risk populations in Israel. *Cell Rep Med*. May 18 2021;2(5):100264. doi:10.1016/j.xcrm.2021.100264

61. Marks M, et al. Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study. *Lancet Infect Dis*. May 2021;21(5):629-636. doi:10.1016/S1473-3099(20)30985-3